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1 Introduction 
 
In the history of medicine, there was always the wish to delay the natural process of decay or 
malfunctions in the body caused by normal ageing processes, dysfunction by diseases or in-
jury of important organs. 
A steadily increasing average age of the society in 1. world countries shows the success of 
medical treatment, made possible by a constant growth of knowledge about mechanisms as-
sociated with pharmacological agents and ongoing development of improved surgical meth-
ods and medical equipment.  
But, especially in a population of growing age, the number of so called end-stage diseases 
where all therapies fail is rising. For these patients, a solid organ transplantation is a necessity.  
 
1.1 Transplantation – Data and Facts  
The history of lung transplantation (LTX) began 1940 with the Russian scientist Vladimir 
Demikhov who made the first attempts to transplant a lung from one animal to another and 
showed that it was technically possible. But the lack of understanding in the process of rejec-
tion and the absence of immunosuppressive treatment left no chance in a real long-term sur-
vival.
1
 In 1960, Sir Frank Burnet and Peter Medawar shared the Nobel Prize in medicine for 
their pioneering work in the understanding of the immunological process upon rejection.
2
 Due 
to improvements like the invention of the heart-lung machine and immunosuppressive drugs, 
the first successful lung transplantation with an adequate long-term survival was performed in 
1983 by Dr. Joel Cooper at the University of Toronto.
3
 From this time on, LTX became a 
therapy for endstage pulmonary diseases.  
In an overview from the Association of Heart and Lung Transplantation in 2010, 183,222 
persons were recorded in available Organ Procurement and Transplantation Network (OPTN) 
data as living with a functional transplanted organ – this means an increase of 1.7% compared 
to 2006 and a 56.6% increase since 1999.
4
 
In 2008 100,597 patients were registered in organ waiting lists in the United States. This is an 
increase of 3.7% people waiting for an organ since the end of 2007. The lung - waiting list 
increased even by 8.8%.
4
 
Unfortunately, the donation of organs has not kept pace with this rising demand.
5
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Beside this, the LTX has always occupied a special place among all other solid organ trans-
plantations, as it results in poorer graft and patient survival rates than most other transplanta-
tions. Nevertheless, the postransplant one - year patient and graft survival increased to 75% in 
1995 and became over 80% in 2008.
4
 Despite that improvement, this value is still low com-
pared to survival rates of other solid organ transplants of approximately 90%. The situation of 
recipients of lung transplants leaves and even more dramatic impression when an average 5 
year graft survival of only 54.4% is considered.
4
 This phenomenon has a major cause: the 
lung is believed to be very prone towards being damaged. Often, it is already pre-damaged 
due to trauma, aspiration, resuscitation attempts or complication on the Intensive Care Unit 
(ICU).
6
  
As a result, more than 60% of potential lungs have to be discarded by reason of poor organ 
function. Studies repeat that more than 60% of potential lungs have to be discarded.
5, 7
 A 
study from Victoria, Australia has shown that only 17% of all lung donors were transplantable 
whereas 88% of these donors could still donate a kidney.
7
 Therefore, many attempts have 
been made to enhance utilization of donor lungs and to maximize LTX opportunity. Even 
‘extended criteria’ organs with history of asthma, airway secretion or smoking donors are thus 
transplanted with more or less acceptable short-term results.
8-10
 In some centres, living related 
donor lungs or donation-after-cardiac-death (DCD) donor lungs have also been used.
11-13
 The 
addressed studies imply that a main problem is finding the ‘right’ donor in the ‘right’ time to 
enable an optimal preparation of an organ. 
Another big issue occurs in the preparation itself, as it causes and intrinsic ischemia and thus 
a probable reperfusion injury. Amongst all other organs, the lung has the lowest ischemia tol-
erance. Thus, the most important criteria for successful lung transplantation is time! In a study 
from Victoria, Australia 16% of all donor lungs were unusable due to logistical limitations.
7
 A 
critical point is the extended cold ischemia during the period of conservation that correlates 
with a high risk for development of primary graft dysfunction (PGD).
14
 
The following chapters will give an overview about the leading causes of lung graft injury.  
 
1.2 Ischemia and Reperfusion 
Ischemia is defined as the insufficient or complete absence of blood flow in the tissue.
15
 An 
ischemic state is usually followed by reperfusion when blood circulation is partially or com-
pletely restored.
16
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As a matter of fact, oxygen is the livelihood for every single cell. Thus, a lack of oxygen in-
duces a powerful alarming signal that causes a critical and deleterious situation for the af-
fected organ or even the whole organism.
17-20
 Functional accommodation of oxygen is se-
cured via the wide network of arterial and venous vessels that supply the tissue with oxygen-
ated blood from the lung. If the normal blood flow is cut or strongly restricted in a part of the 
circulation system, the tissue will suffer from oxygen deprivation, resulting in hypoxia and 
complete ischemia if this state is kept.
17, 20
 In transplantation medicine, ischemia as absolute 
or relative shortage of blood flow is a state, that can’t be avoided during transplantation. The 
organ has to be taken out of the donor, and therefore cut from the donor’s blood system prior 
to readaption to the recipient’s blood circulation.  
Ischemia in the lung can cause lipid peroxidation and oxidant injury despite the presence of 
oxygen.
21, 22
  
Two kinds of ischemia are differentiated: cold and warm ischemia:  
The ischemia is defined as ‘warm’, if the tissue or organ is kept at body temperature during 
this state. Warm ischemia occurs in organ harvest and transplantation to the recipient as the 
condition of the organ due the detachment from blood circulation and the time during surgery 
until the recipient’s vessels are adapted.  
The ischemia is defined as ‘cold’, if the tissue or organ is cooled down. This happens usually 
during storage and transport and can’t be avoided. Since hypothermia decreases energy re-
quirement and metabolic rate of the organ, temperature seems to play an important role during 
ischemia. It has been shown that the inflicted tissue damage distinguishes between cold and 
warm ischemia due to different types of cells being affected.
23, 24
  
As both forms of ischemia lead to tissue damage, ischemia-time has to be kept as short as 
possible. Many different factors have to be considered like storage time, donor and recipient 
preparation or duration of surgery. In organ storage, a cold ischemic time, which is defined as 
the period of cooling the organ until reestablishment of the blood flow, of 4-8 hours are ac-
cepted. Warm ischemic time depends mostly on the surgeon’s organ preparation and preser-
vation experience.
17
 
 
1.2.1 Ischemia and Reperfusion Injury 
Many approaches have been developed to optimize the methodology of lung preservation 
over the past decade. The prevention and treatment of ischemia reperfusion injuries (IRI) lead 
to a reduction of PGD incidence of approximately 30-15%.
25, 26
 Due to the decreasing num-
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bers of donor organs and the extended donor selection criteria it is even more important to 
understand the mechanism of IRI and to develop better preservation and prevention possibili-
ties. Especially in lung transplantation and the major use of brain dead donor lungs, the un-
derstanding of ischemia and reperfusion (I/R) is essential.  
Ischemia leads to a lack of oxygen, hence hypoxia and was shown to increase the risk of in-
flammation in grafts that may lead to graft failure or rejection.
27
 Hypoxia occurs in the lung, 
when alveolar oxygen pressure drops below 7 mmHg during ischemia, and it induces inflam-
matory response when perfusion is initialized after hypothermia. 
28,29,30, 31,17,32, 33, 20, 33-41
 
One important biochemical entity that responds to hypoxic conditions on a molecular level is 
the hypoxia inducible factor-1 (HIF-1). On previous studies it was reported to reach high lev-
els in inflammatory tissue and is the central research topic of this work.
42
 
Beside its beneficial adaptive effects on long-term hypoxia, it also has the ability to regulate 
several functions of myeloid cells to enhance their stimulation, aggregation, motility and in-
vasiveness.
43, 44
 It also prolongs the lifespan of neutrophils and has an influence on the adap-
tive immunity
45, 46
 
In studies on mountaineers suffering from mountain sickness, it was demonstrated that HIF-1 
influences inflammatory processes and pulmonary edema which was demonstrated 
47-49
 
Under hypoxic conditions HIF-1 has a great effect on the cell via regulation of Vascular En-
dothelial Growth Factor-A (VEGF). VEGF leads to increased permeability of the endothelium 
and a formation of fenestrae in the capillary sheet, which are relevant steps towards the de-
velopment of edema.
50-52
 This condition follows a swelling of alveolar interstitium and a 
flooding of the alveoli. Accumulated extravascular water and the swelling leads to a critical 
disturbance of the mechanical function and a disablement of the gas exchange which may end 
in PGD afterwards.
53-57
 
Additionally, several mechanisms affect the graft during the hypothermic storage of organ 
transplants and may lead to activation of inflammatory mediators that lead to inflammation 
and injury at the time of reperfusion.
17
 Hypothermia, for example, has an effect on the func-
tionality of many enzymes, as most of them show a 1.5-2.0 fold decrease in their activity for 
every 10°C decrease in temperature.
58
 Understandably this effect is favourable as it reduces 
the metabolic processes. But many downregulated or even stopped enzymic function results 
in dysfunction of critical mechanisms to keep the balanced state in the cell.
59
 
One of these critical points is the inactivation of sodium pumps, like the Na
+/
K
+ 
ATPase. This 
ATP dependent enzyme is accountable to perpetuate the intracellular electrolyte concentration 
by shuttling potassium ions (K
+
) from the outside of the cell into the intracellular fluid and 
Introduction 
 
8 
sodium ions in the opposite direction. Thus, a high K
+
 and a low Na
+
 concentration inside the 
cell is maintained which has to be high in intracellular fluid and sodium ions (Na
+)
. Conse-
quently the Na
+/
K
+ 
ATPase enables the adequate clearance of the alveolar cell fluids.
17
 
Under hypothermic conditions, the function of the sodium pumps is diminished but can be re-
established upon reaching a temperature of 37°C under the premise that there is no damage to 
the endothelial cells.
60
 This temporary deficit leads to an accumulation of sodium in the intra-
cellular fluid and a passive influx of chloride. This also causes cell swelling and accumulates 
with the swelling cause by HIF-1 upregulation in the time of repefusion.
17, 53-57
 
One important consequence of ischemia and reperfusion injury is the upregulation of certain 
molecules on the cell surface membrane. These adhesion molecules play an important role in 
modulating the inflammatory response. They can be differentiated in three families: selectins, 
immunoglobulin superfamily and integrins. They are upregulated on pulmonary endothelial 
cells during ischemia and are important for leukocyte emigration. The emigration of leuko-
cytes depends on different events mediated by adhesion molecules: rolling, adherence, activa-
tion and extravasation. The activation and proper adherence appears when leukocyte ß1 or ß2-
integrin bind to endothelial cells which then express intercellular adhesion molecule-1 
(ICAM-1) or vascular endothelial adhesion molecule-1(VCAM-1). The extravasation into the 
tissue is dependend on integrin-immunglobulin interactions which involves ICAM-1 and 
platelet endothelial cell adhesion molecule-1.
17
 
Under hypoxic conditions, endothelial cells and macrophages develop inflammatory proper-
ties which lead to impaired blood rheology during reperfusion and cause critical damage in 
IRI.
61,62-64 
Another factor is Endothelin, a vasoconstrictor, 10 times more powerful than Angiotensin II. 
It is released via endothelial cells and its expression is predominant in the lung.
65
 It stimulates 
the production of cytokines by monocytes/macrophages and promotes the retention of neutro-
phils in the lung.
66
 It is known to accumulate in lung tissue before and during the first hours 
after reperfusion
67, 68
 – high levels even lead to increased expression of VEGF and cause a 
higher vascular permeability.
69
 
Proinflammatory factors are released in many organs after I/R and this has also been shown 
also for the lung.
70
 Measurable amounts of pro- and anti-inflammatory cytokines like TNF-α, 
IFN-ɣ, IL-8, Il-10, IL-12 and IL-18 were found in human lung transplants during cold ische-
mia and after reperfusion.
71
 Most of them decrease after reperfusion except IL-8 which shows 
a significant increase. While most donor parameter like oxygen tension, consequences of 
brain death or smoking history did not appear to influence the cytokine level, it was found 
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that IL-10 level, an anti-inflammatory cytokine, correlated inversely with donor age.
72
 IL -10 
and IL-4 play an important role as anti-inflammatory cytokines in lung transplantation pa-
tients. Especially IL-4 seems to take part in diverse immunomodulatory mechanisms – some 
are part of the inflammatory axis of chronic rejection, but interestingly also in anti-
inflammatory ways.
73-75
 
Another relationship was found between IL-8 and graft function in human lung transplants.
71
 
This potent chemokine promotes neutrophil migration which rapidly increases after reperfu-
sion. The IL-8 concentration 2h after reperfusion is negatively correlated with signs of lung 
injury like the ratio of partial oxygen tension of alveolary to the fraction of O2 in inhaled air 
(PaO2/FiO2) and mean airway pressure. With Acute Physiology and Chronic Health Evalua-
tion Score, on the other hand, it has a positive correlation during the first 24 h on ICU.
71
 
Besides that, the C-X-C chemokine receptor type 4 (CXCR4) has been demonstrated to be 
very active in the inflammatory process of acute lung injury and the development of bron-
chiolitis obliterans. The number of CXCR4 positive cells is increased in lungs of patients that 
suffer from this form of chronic rejection. It is also involved in several fibrogenic processes 
after lung injury. 
76-78
 
 
1.3 Primary Graft Dysfunction (PGD) 
The primary graft dysfunction (PGD) is a multifactorial injury that occurs in the graft and 
developed within the first 72 h after transplantation. It presents itself with acute lung edema, 
severe hypoxemia and diffuse alveolar damage.
14, 79-81
 
The transplantation process consists of many steps, that all represent bottlenecks in adequate 
organ function. Beside the harvesting process, that is critical, the selected organ has to un-
dergo the preservation process, transport and implantation. All these manipulation steps may 
lead to PGD which affects an estimated fraction of 10-25% of lung transplants and is the lead-
ing cause of early post-transplantation morbidity and mortality.
79-87
 
Unfortunately, these necessary procedures can damage the lung even when all of them are 
performed under optimal conditions just by the mere mechanical manipulation of the organ.
11-
13
  
Risk factors to develop a PGD are prolonged mechanical ventilation, aspiration pneumoni-
tis/pneumonia, trauma, or hemodynamic instability after brain death.
88
 
It is also known already, that brain death itself has a critical effect on organ function by inter-
fering with the whole homeostatic regulatory system and producing a severe disorganization 
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in the endocrine function. The so called ‘cytokine storm’ leads to significantly higher levels 
of inflammatory cytokines.
89-94
 This may end up in decreased tolerance to ischemic periods 
and therefore augment the susceptibility for ischemia reperfusion damage and, later on, an 
alloimmune response.
17
 
Pathological mechanisms like the constitution after brain death, pulmonary ischemia, cold 
organ preservation in due to organ transport and reperfusion are also critical factors which 
lead in the end to PGD.  
Especially important for this work and reported as an important driving force is the injury 
caused by cold or warm ischemia and following reperfusion (IRI) which is described in chap-
ter 1.2.1.
17, 88,
.
61, 70, 95, 96
 
It has been shown that there is a connection between PGD and chronic allograft rejection as 
persons suffering from PGD have elevated proinflammatory mediators during early post-
transplant period and increased development of de novo anti-Human Leukocyte Antigens 
(HLA)/Multi Histocompatibility Complex (MHC) type II antibodies.
97, 98
 
The worst form of PGD is described to occur after 48 hours. It is not only shown, that there is 
a relation between PGD and the bronchiolitis obliterans syndrome (BOS), which is the clini-
cal form of chronic rejection.
99-101
 Some studies also revealed that an increase in PGD sever-
ity is correlated with decreased short- and longterm survival.
102
 30-Days mortality rates are 
eightfold higher in patients with severe PGD compared to those without.  
During organ injuries like PGD, selfantigens are exposed and lead to a potential activation of 
autoimmune response. A special protein, Collagen type V - a major collagen in the lung, 
seems to play a crucial role in this as it seems to be an antigen in the lung if released as a 
fragment.
97, 103
  
The damage to epithelium and microvasculature leads to excessive fibroproliferation and tis-
sue repair. The local ischemia caused by microvasculature damage stimulates HIF-1α and, 
therefore, angiogenesis which is required to support chronic inflammation and fibrooblitera-
tion.
104-106
 
 
1.4 Rejection – different Faces, different Causes 
Although this work concentrates on the early phase of ischemia and reperfusion injury and 
primary graft dysfunction in the first 48 h, aspects of longterm rejection triggered via the im-
mune system will be shortly addressed with this section.  
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Following the cascade of events, not only complement cascade, cytokines and chemokines are 
lerted, but also other parts of the innate immune system like neutrophils and macrophages. 
The inflammatory reaction due to IRI is believed to be predominantly governed by an innate 
immune response.
19
  
The immune reaction via leukocyte activation can be parted into two stages – an early and a 
delayed phase of reperfusion. The early phase is known to depend primarily on donor charac-
teristic determinants, whereas the delayed phase is promoted by recipient dependent.
107
 Neu-
trophils mediate the early phase by producing local microvascular and parenchymal damage. 
Later on monocytes and macrophages are infiltrating the tissue and may augment the injury 
phase.
41
 
Despite the observation that the trafficking of T-cells into an organ was followed by IRI, it 
was believed that they only have the role of ‘passive observers’. Nowadays many studies sup-
port the assumption that T-cells are direct mediators of IRI in many organ systems.
108-115
  
But besides the destructive function of T-cells, new data show the potential role of lympho-
cytes in the healing and recovering process. It was shown that CD8
+
 and CD4
+
 deficiency was 
associated with lower healing response.
116-119
  
Additionally evidence for the existence of regulator or suppressor T-cells which are capable 
of many different functions including the modulation of the immune system has been gath-
ered.
119-122
  
The most feared form of complication besides an infection due to the application of immuno-
suppressive agents is the rejection of the graft itself. Acute rejection affects almost 55% of all 
transplant patients within their first year after transplantation.
123
  
The local innate immune activation and constant activation of immune response due to noxae 
from the environment contribute to the high rates of rejection of lung transplants.
123
 
Rejection is a complex mechanism that is divided in different stages and severity, which are: 
hyperacute, acute, chronic and subclinical rejection. The classification into one of these cate-
gories depens on the time of onset after transplantation.
124
 
Hyperacute rejection occurs minutes to hours after transplantation and is mainly caused by 
pre-sensitization of the tissue. It is the result of alloantibodies and complement fixation.
124
 
Some patients may already have developed anti-MHC/HLA antibodies due to pregnancy, 
transfusion or a previous transplantation. This antibodies react with donor antigens, leading to 
accelerated humoral rejection and bronchiolitis obliterans syndrome (BOS) or to hyperacute 
rejection with immediate graft loss.
124
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Another form distinguished from hyperacute rejection but showing similar clinical signs is 
acute antibody mediated rejection (AAMR) that is known to occur any time after transplanta-
tion.
124
 It manifests in a rapid increase of serum creatinine concentration and shows a resis-
tance to therapy with steroids or T- cell specific agents.
125, 126
 AAMR has a poorer prognosis 
than a pure T- cell mediated acute rejection.  
Both, hyperacute rejection and AAMR present themselves clinical with parenchymal injury, 
fibrinoid arterial necrosis including capillaries that are congested with neutrophils, macro-
phages and thrombi consisting of platelets and fibrin.
127-130
 
Acute lung allograft rejection, also known as lymphocytic bronchiolitis is defined as perivas-
cular or peribronchiolar mononuclear inflammation.
123
 It may occur after a few days but may 
also take years until onset.
123, 124
 It is the result of a response of antigen specific T- cells 
and/or antibodies that show alloreactivity in the graft.
124
 Its frequency and severity seem to be 
the most critical risk factor for the development of BOS, the clinical form of chronic rejec-
tion. This fact limits the survival to 50% at 5 years after transplantation.
131, 132
 
One of the most problematic systems in transplantation is the recognition-system which en-
ables the organism to differentiate cells into self and non-self. In vertebrates it has evolved 
into a very complicated system that almost every cell of a body is linked to. This Major His-
tocompatibility Complex (MHC), or in humans Human Leukocyte Antigene (HLA) is a pro-
tein complex encoded by a set of very closely linked genes. This complex presents antigenic 
peptides that regulate immunological response by presenting these antigens to T- cells. 
MHC genes are traditionally divided into two groups – MHC I and II. MHC class I genes are 
expressed on the surface of most nucleated cells including epithelial cells. The molecules of 
these genes mainly present endogenous peptides to CD 8
+
 T- cells.
123, 124
 
MHC class II genes are constitutively expressed on B- cells, monocytes, dendritic cells and 
other antigen presenting cells (APCs). They are upregulated on many other cells under in-
flammatory conditions.
123
 
After donor APCs die out or are destroyed, the dendritic cells of the recipient process present 
the alloantigens to the recipient T-cells.
133
 
Another critical point relies within the blood group antigen that represents a distinctive mark 
for the immune system.
124
 
Even if there are still many mechanisms not fully understood, commonly, acute rejection in-
volves the recruitment and activation of recipient lymphocytes which are mainly effector T-
cells. This cause lung allograft injury and later on, its loss.
133
 They also provide help for B- 
cell memory, antibody class switching and affinity maturation. This is controlled by many 
Introduction 
 
13 
different T- cell derived cytokines and co-stimulatory factors, recognizing receptors at the 
surface of B- cells. B- cells produce long living plasma cells in the tissue and migrate to the 
bone marrow where they continue antibody production indefinitely without requiring T- cell 
help anymore.
134
 
Chronic rejection, also known as bronchiolitis obliterans (BO) is a leading cause of morbidity 
and late mortality after one year in lung - transplantation patients.
100
  
Normally the first sings are recognized clinically by sustained declined expiratory flow rate at 
least over three weeks when other reasons have been excluded.
135
 In advanced BO there is a 
wide spectrum from partial to completely acellular fibrotic obliteration where only a scar re-
mains of the airway lumen.
100, 135, 136
 This small airway destruction may lead to accumulation 
of foamy macrophages and mucostasis in the distal airspace.
136
 Alloimmune independent fac-
tors like primary graft dysfunction or alloimune dependent as acute rejection are thought to be 
associated with BO.
137-139
  
Pro- and anti-inflammatory cytokines play a critical role in wound repair and the progression 
of BO. Different types of immune response interact during chronic rejection.  
Type 1 immune response goes mainly together with cell-mediated immunity and results in 
production of IL-2, IL-12, IFN-ɣ, lymphotoxin that drives cytotoxic T-lymphocytes and de-
layed hypersensitivity response.
140
 
Type 2 immune response is identified via production of IL-4, IL-5, IL-13 and goes along with 
humoral immunity.
140
 
Type 17 immune response leads to IL-17 and IL-23 production and results in 
autoimmunity.
140
 
The type of the three immune responses is considered to change via the nature of alloantigens 
and the pattern of cytokines released into the environment.
141
 Chemokines also have a role in 
this complicated process as growth factors and humoral factors like the complement frag-
ments.
140
 
 
1.5 Hypoxia Inducible Factor - 1 (HIF-1)  
Oxygen serves as an important reactant in every cell – it is crucial for metabolic processes in 
mammals and serves as an electron acceptor in the reaction during ATP formation. Therefore, 
the status of hypoxia, which is defined as a local or even general pathological status of de-
prived oxygen supply, is a severe condition that leads to cell damage if the status is not nor-
malized quickly. In highly developed organisms like mammals, a very specific system of 
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oxygen sensing and regulation factors has evolved, to resolve or reduce the negative effects of 
hypoxia to the single cell but also to the complete organ.  
This state of emergency is moderated by the transcription factor HIF-1, which was first de-
scribed by Semenza in 1992.
142, 143
 The first discovered HIF-1 effect was the induction of 
erythropoeitin (EPO) upon hypoxia thus increasing the O2 carrying capacity of the blood.
144, 
145
  
HIF-1 consists of two subunits which form together the activated HIF-1 protein as a het-
erodimer. Both subunits were shown to be basic helix-loop-helix (bHLH) PAS-proteins who 
are known to be regulated in their expression by oxygen tension.
142
 PAS-proteins (named af-
ter the first isolated proteins from this family of Drosophila melanogaster – PER-ARNT-
SIM
146, 147
) always contain two internal homology units and are responsible for protein-
protein interactions. The subunits form contacts to the DNA in the major groove
148-150
 and 
were named as HIF-1α and the already known HIF-1ß.151 HIF-1α and -ß units were detected 
in all tissues of rodents and humans.
143
  
HIF-1α is a 120 kDa bHLH-PAS protein142, 152 and is only detectable during hypoxic condi-
tions in the cell of adult mammals.
143, 153
 High levels of HIF-1α under non hypoxic conditions 
are only found in embryonic stem cells and are due to the special situation in the tissue before 
and during neovascularisation.
143
 The half life of this protein is very short and below five 
minutes.
153
 A detection of HIF-1α is possible after 30 minutes of exposure to hypoxia (1-2% 
O2) and it has a peak between 4-8h under hypoxic conditions. Endogenous HIF-1α is local-
ized in the nucleus of hypoxic cells.
153
 
HIF-1ß was also formerly known as ARNT (Aryl Hydrocarbon Receptor Nuclear Transla-
tor).Its mass differs between 92-94 kDa and different isoforms exist.
142
 Unlike to HIF-1α, it is 
constitutively expressed and present in the nucleus of cell.
152, 154
  
The regulation of HIF-1α and therefore, the functionable HIF-1 protein is performed via dif-
ferent steps of ubiquination and proteasomal degradation in which the von-Hippel-Lindau 
product (pVHL) plays a crucial role.
153, 155
 Under normoxic conditions, HIF-1α is 
polyubiquinated via pVHL by binding to HIF-1α only when a conserved proline structure is 
hydroxilated and, thus, degraded by the proteasome. 
155-159
 Responsible for this reaction is the 
HIF-1α oxygen-dependent-degradation-domain (ODD).155, 160-162 The hydroxylation of the 
proline is oxygen dependent and ceases to proceed under hypoxic conditions.
163
 pVHL is 
known to be intact in HIF-1 overexpressing tumor cells and as the interaction between HIF-1α 
and pVHL is iron-dependent, it can be blocked by iron chelators.
153, 155, 163
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This leads to accumulation of HIF-1α, diffusion into the nucleus and dimerisation with the 
always expressed HIF-1ß subunit.
164, 165
 The now functional HIF-1 transcription factor starts 
gene transcription by binding to the hypoxia respond element on HIF-1 regulated genes. HIF-
1 binds to the hypoxia response element (HRE) on the target which contains functionally HIF-
1 binding sites.
143, 152
 
 
 
Figure 1: HIF-1 pathway (Created according to literature 166, 167). a) Normoxia: HIF-1α is 
hydroxylated via prolyl hydroxilases (PHD 1,2,3) in presence of oxygen, iron and other factors (I). 
The hydroxylated HIF-1α is now recognized by pVHL which binds to it (II). A multisubunit ubiquitin 
ligase complex binds and tags HIF-1α with polyubiquitin (IV). This enables recognition by the pro-
teasome and HIF-1α is degradated (V) b) Hypoxia: The proline hydroxylation is inhibited and pVHL 
is not able to bind HIF-1α. Proteasomal degradation is blocked and HIF-1α accumulates in the cytosol 
(I) HIF-1α now translocates into the nucleus where it dimerises with HIF-1ß and recruits transcrip-
tional co-activators like p300/CBP for its full transcriptional activity (II). This complex binds to the 
hypoxia response element (HRE) in the promoter of target genes and activates the transcription of 
HIF-1 regulated genes that fulfil many different functions as cell survival and proliferation, proteoly-
sis, angiogenesis, erythropoiesis, pH regulation, apoptosis and glucose metabolism. VHL = protein 
product of von Hippel Lindau transcription factor; HIF = hypoxia inducible factor; HRE = hypoxia 
response element. 
 
The list of identified target genes regulated by HIF-1 is steadily growing and they are encod-
ing important products for hypoxia response, oxygen homeostasis, angiogenesis, glycolysis 
and tumor growth, but according to new studies, also inflammatory processes.
143, 155, 168
 HIF-1 
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regulated genes can be divided in two groups – fast acting and long acting genes. The fast 
acting genes are regulated within minutes.
169
 
 
 
HIF-1 is also shown to mediate the configurational change of endothelial cells, leading to 
gaps in the endothelial barrier.
171
 
The inflammatory role of HIF-1 is clinically observed under extreme low oxygen conditions 
that high-altitude mountaineers are exposed to. This people often show lung and brain edema 
as well as the so called systemic inflammatory response syndrome.
47, 49, 172, 173
 And as hypoxia 
leads to inflammation, inflammation itself is also causing hypoxia which ends in a downward 
circle concerning acute lung injury and lung transplantation.
174, 175
 
To these inflammatory effects adds the increase of VEGF and therefore the high permeability 
of the tissue after the restoration of the blood flow which leads to early graft dysfunction.
176-
180
 
So it can be postulated, that, even if the effects of HIF-1 are supposed to prevent damage to 
cells and organs during hypoxia by effects like the amplification of glycolytic activity or the 
increase of hemoglobin levels, in the endothelium rich tissue especially in the transplanted 
lung, the sum of all effects leads to a damage of the tissue. This seems to be mostly an effect 
of the fast acting genes as VEGF and primary graft failure can be correlated with this. 
67, 69, 169, 
181
 
Figure 2: Gene products of HIF-1 and their function in the organism. The most important functions 
and genes for this work are bolt. (For abbreviations see appendix, created according to literature170). 
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1.5.1 Vascular Endothelial Growth Factor (VEGF) 
Most important for this work is the effect of HIF-1 and its gene product, the Vascular Endo-
thelial Growth Factor (VEGF), during lung damage. The members of the VEGF family are 
dimeric proteins with a molecular weight of approximately 45 kDa.
182
 VEGF, one of the iso-
forms, is a major regulator for blood vessel formation and function, but it also has influence 
on permeability and inflammatory potential.
183, 184
 
VEGF is examinated best in endothelial cells and highly expressed in lung epithelial cells of 
adults and cardiac myocites.
185
 It is the most important angiogenic factor that can be induced 
via HIF-1 under hypoxia.
186
 
Besides the benefits of the long acting effect of the gene product VEGF, which is important 
for the angiogenesis, it has a destructive effect on the lung through the short acting mecha-
nisms. VEGF is a potent mediator of endothelial barrier dysfunction which is dramatic in the 
vulnerable system of the lung – the pulmonary vascular permeability is bluntly increased.168 It 
is 50.000 times stronger than histamine in its potency to increase vascular permeability.
187
 It 
is able to induce fenestrations in venular and capillary endothelium within 10 min and its ef-
fects may be correlated with organ failure.
67, 181, 188-193
 VEGF, as one of the fast acting genes 
is known to be upregulated during ischemia in many organs and it is increased during ische-
mia in the lung.
194-197
 Its receptors like the VEGF-receptor 1 (Flt-1), VEGF-receptor 2 (KDR) 
and Endothelin-1 (ET-1), play essential roles during ischemic damage. Also genes like 
VCAM-1 and ICAM-1 which regulate cell adhesion to the endothelium are important in this 
process.
69, 198, 199
  
Even if VEGF is very specific for endothelial cells, it has also an effect on other cell types, 
which is most important for its malignant effect during transplantation, on inflammatory cells 
like monocytes and mast cells.
200
 VEGF was also found to play a role upon neutrophil activa-
tion which are substantially involved in acute lung injury
201-203
 
Although VEGF bears positive effects like neovascularization, this was described to be of less 
importance in the first critical hours of lung injury as neovascularization takes several days 
due to the duration of endothelial mitosis and migration whereas the effect on edema was 
shown to occur already after 24 h.
56, 204, 205
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1.6 Deguelin 
Deguelin is a rotenoid which belongs to the flavonoid family and is described most often in 
literature to exhibit antiangiogenic properties.
208, 209
 
It was structurally first described in 1932 together with its derivate Tephrosin.
210
 It is the se-
cond most important ingredient of the pesticide cubé resin besides Rotenone which was men-
tioned together with Deguelin already in 1902.
211, 212
 Cubé resin is a root extract from differ-
ent kinds of plants from the family of the fabacea, mostly Lonchocarpus utilis (Cubé), L. 
urucu, and Mundulea sericea. It was used as a botanically pesticide, especially against in-
sects, but also for selection of fish in American sport-fishing.
212
 It consists of different 
rotenoids - four major active ingredients, but studies could identify almost 29 minor 
rotenoids.
212
 The most important ingredients are with the highest percentage Rotenone (44%) 
Figure 3: The overall hypothesized role of VEGF in acute lung injury. a) The alveoli are confronted 
with a noxae as hypoxia or stress (I). The release of VEGF is stimulated and huge amounts are se-
creted from type II cells and alveolar macrophages (II). The epithelial-endothelial barrier is now ex-
posed to high concentrations of VEGF (III). The high amounts of VEGF lead to gap formation and 
vascular leakage which ends in interstitial edema. It also affects macrophages and neutrophils (IV). 
Due to the gap formation, liquid can enter the alveolar lumen and destroy the function of the surfactant 
and the gas-exchange (V). (Created according to literature206, 207) 
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and Deguelin (22%), followed by derivates of the two main ingredients, Rotenolon (6.7%) 
and Tephrosin (4.3%).
212
 
The ratio of Rotenon to Deguelin is 2.0 but varies 
due to the natural product and in different part of 
the plants.
213
 As all rotenoids differ only in changes 
of substituents at the dihydrofuran or the pyran 
ring, respectively, almost all have a specificity in 
the inhibition of complex I (NADH:ubiquinone 
oxidoreductase) and the 12-O-
tetradecarnoylphorbol-13-acetat induced ornithine 
decarboxylase (ODC).
209, 212
 Both mechanisms are 
most important for their toxicity and also their 
chemopreventive activity. Due to their chemical 
similarity, the most effective way to obtain 
Deguelin with high purity is the chemical conver-
sion of Rotenone to Deguelin.
210, 213
  
Deguelin itself was examined especially in cancer-models. In contrast to Rotenon, it is opti-
cally inactive. It contains two hydrogen atoms that can be removed even under mild oxidative 
conditions which leads to a double bound instead and creates the so called Dehydrodeguelin. 
Hydroxilation of this double bound to a creates Hydroxydeguelin, also known as 
Tephrosin.
210
 
Although Rotenone was the first identified substance in cubé resin and has the largest relative 
proportion, Deguelin shows some benefits for clinical use. It posesses the same characteristics 
as an inhibitor and is similar in its potency compared to Rotenone.
213
 Recent data from 2011 
show some significant differences between Rotenone and Deguelin in their pharmacological 
mechanism, even if their chemical structure seems to be so close. Deguelin does not show a 
pronounced inhibition of tubulin polymerization, which is an important factor in their differ-
ent toxicity.
214
 
In contrast to Rotenone, Deguelin is 2 x less toxic when injected subcutaneously to rats. LD50 
levels in mice are 4.3 mg/kg and,thus, better than for Rotenone with 2.3 mg/kg. Measured 
brain levels showed a better outcome for Deguelin with 0.18 ppm after 2 h compared to Rote-
none with 0.39 ppm.
213
 
Deguelin showed also a good acceptance when administered over a long time to animals 
without systemic toxicity (Table 1).
215
 The maximum tolerated dose of Deguelin in rats is 
 
Figure 4: 3D model of Deguelin combined 
with the LEWIS-structure. White: carbon, 
red: oxygen, hydrogen left out for 
clarity.210 
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high (4 mg/kg) compared to the effective dose of Deguelin needed (100 nM – 1 µM).215, 216 
Also no cytotoxic effect on physiological cells could be demonstrated up to concentrations of 
10 µM.
209
 
 
Table 1: Pharmacokinetic properties of Deguelin. Modified after Udeani et al.217 
Mean residence 
time 
Terminal half 
life 
Total clear-
ance 
Elimination via 5 days (i.g.) 
feces urine 
6.98 h 9.26 h 
4.37 l/h per 
kg 
eliminated Unchanged eliminated Unchanged 
58.1 % 1.7 % 14.4% 0.4 % 
 
Tissue distribution after i.v. injection > from left to right 
Heart Fat Mammary gland colon liver kidney brain lung 
Tissue distribution after i.g. administration > from left to right 
Perirenal fat heart Mammary gland colon kidney liver lung brain skin 
 
It was shown that Deguelin has also an effect on tumor growth like it was demonstrated for 
Rotenone ealier.
208, 213
 Deguelin could be used successfully as a chemopreventive agent in the 
therapy against various cancer types of lung, skin and intestine.
215, 216, 218-222
 
It has an inhibiting effect on ODC, which is the catalyst for the decarboxylation of ornithine 
to yield putrescin that is converted into higher polyamines and has a crucial function for cellu-
lar proliferation.
209
 The anti-proliferative effects were also demonstrated for the expression of 
cyclooxigenase-2 and the phoshatidylinositol-3-kinase (PI3K)-Akt mediated signaling.
215, 219-
221
  
Although the concrete mechanism of the inhibition still remains unclear, different studies 
showed that Deguelin has an inhibiting effect on HIF-1α and its transcription product 
VEGF.
209, 216
 It could be demonstrated, that Deguelin does not affect HIF-1α through the inhi-
bition of the ROS- and Akt-pathway.
209, 222
 It leads to a degradation of HIF-1α protein where-
as the inhibiton of the transcriptional activity of HIF-1α is visible at a dose of 10 µM of 
Deguelin treatment.
209, 216
 Deguelin can also inhibit the de novo synthesis of HIF-1α and re-
duce the half-life of already synthesized protein.
216
 
Besides that, it was suggested that Deguelin affects the heat shock protein 90 (Hsp90) that 
protects HIF-1α from oxygenation and therefore degradation, but recent studies showed no 
affinity to Hsp90.
214, 222
 The same study showed that Deguelin has an  inhibitory effect on the 
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respiratory chain in the mitochondria. 
214
 This seems to lead to more cytosolic O2 and there-
fore to destabilization of HIF-1α. 223 
 
1.7 Lung Transplantation in Animals as Models to investigate 
post Transplantional Lung Injury 
To get a better understanding of the complex mechanisms in transplantation, animal models 
are always the method of choice. They give the possibility to examinate not only the short-
time reaction but also the long-term effects on the graft and the recipient’s organism. There-
fore, various experimental lung transplantation models have been used to develop a satisfying 
methodology. The first models were based on dogs.
224
 Later on due to the immense cost in 
livestock for large animals and the advantage of inbred strains, rats became the preferred 
model
225
. On the one hand, the possibility to discriminate between immunologic and 
nonimmunologic events by using inbred rat strains was a valuable benefit but on the other 
hand, the small structure of the rat lung was a new great challenge for the surgeon.
226
 Only the 
inventions in microsurgical equipment and techniques since 1963 made working on the small 
tissue structures possible and the common transplantation was refined in 1989 by Mizuta et 
al
227
 by using small cuffs that could be stuck into the new structure and just tied instead of the 
complete suture that was used before. This was a significant improvement as an adaption via 
surgical suture technique takes long time and is due to leakage involved with a high risk of 
great blood loss or air leakage through the bronchus. This so called cuff-technique was modi-
fied over the years to minimize the foreign body reaction to the material of the cuff and the 
surgical method itself, but is still used as a well established animal model for lung transplanta-
tion.
228-232
  
 
1.8 Physiology of the Rat Lung compared to Human Lungs  
The lung of the rat bears some species-specific differences to other mammals and also the 
human lung on anatomically and physiologically level. Starting with the most obvious, the 
rat’s lung lobes are segmented into five lobes: one left lobe and four on the right side. The so 
called postcaval lobe of the right lung lies in direct contact with the diaphragm and is notched 
to accommodate the vena cava caudalis, therefore called postcaval lobe (Figure 5). 
Other than in humans, the removal of the right lung bears much more difficulties, than the left 
lung. The lung weight is related to the size of the body, which should be taken into considera-
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tion when choosing donor and recipient animals. The important vessels also show some dif-
ferences to humans – besides the fact, that rats only have one pulmonary artery and vein for 
each side, which is very good for the transplantation method. The pulmonary vein in the rat is 
also thicker than in most other mammals, due to the presence of striated muscle fibers that are 
contiguous to those of the heart.  
 
Figure 5: Schematical drawing of the heart-lung complex. RL = right lung lobe; s = superior part; 
m = median part; i = inferior part; PL = post caval lobe; LL = left lung lobe; D = rest of diaphragm; 
Tr = trachea; O = oesophagus (Illustration by Ockelmann®) 
 
The pulmonary artery in the rat belongs to two types of elastic and muscular ones
233
 The elas-
tic artery type has lots of extracellular matrix in the media and smooth muscle cells that are 
connecting the neighboring elastic laminae. The muscular artery has only few extracellular 
matrix and the smooth muscle cells enclosing the lamina circumferentially.  
The blood flow in the lungs is somehow centralized to the hilus-regions of the lung lobes in 
the conscious resting rat, whereas it is only less in the peripheral regions.
234
 
The innervation of the lung is different from most other mammals as rats do not have adren-
ergic nerve supply to the bronchial muscle and therefore, the bronchoconstriction is controlled 
via vagal tone instead of sympathetic tone in humans and most other mammals.
235
  
The lymphatics play a critical role, especially for clearing the lung fluid and therefore, have a 
special function during edema. One very big potential for edema-building in the rat is the po-
sition of the capillaries which are upstream from the veins that are supplied with venous 
sphincters
236
 – this leads to a constricting potency that can control lung perfusion and there-
fore edema. Besides that, an increased number of lymphatics are positioned to this sphincters 
that help to moderate edema.
237
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The respiration itself is regulated via response to tissue CO2 changes in the medullary respira-
tory center but beside this, the so called carotid ‘glands’ or bodies seem to play a role – they 
are located on each side of the neck in the bifurcation of the carotid artery. In the adult rat, a 
respiratory average of about 85 breaths/min is reached with a minute ventilation of about 
100ml/min and an average tidal volume of 1.5 ml.
238, 239
 
Regarding the histological structure of the lung, it contains 74% of alveolar tissue and 26% of 
nonalveolar tissue.
240
 The typical alveolar cells are flat pneumocytes type I which are part of 
the barrier for the gas-exchange and round pneumocytes type II that are responsible for sur-
factant secretion. Both line the alveoli.
241
 
Other cell types are goblet cells that have a function in producing mucin and glycoproteins
242
 
to react on airway insults – they work together with cilial cells that remove the produced mu-
cus upwards the airway. Then, there exist septal cells in the alveolar interstitium that contain 
contractile filaments as actin, desmin and vimentin.
243
 They can change the architecture of the 
air-blood barrier via contraction and therefore influencing the ventilation and perfusion ratio.  
The alveolar walls consist of three layers. The epithelial layer lining the alveolar space, a 
basement membrane and an endothelial cell lining of the capillary lumen.
244, 245
 All layers are 
relatively thin (about 1.5 µm). The alveoli are covered with the surfactant that has different 
functions as tension-lowering and maintaining the patency of conducting the airways.
246
 
Phospholipids and particulary phosphatidylcholines are essential components of it – whereas 
in most mammals they are monounsaturated, the rat has a high level of polyunsaturated phos-
pholipids.
247
  
  
1.9 Aims of the Study 
The suppression or inhibition of the deleterious effects that result from transplanting an 
allogenic organ is of great interest in transplantation medicine, as it is the common donor situ-
ation. As the complete elimination of recognition of the donor organ as ‘foreign’ in the recipi-
ents body is still more an utopia than a realistic option, the focus has to be laid onto reduction 
of the inflammatory reaction.  
As ischemia and hypoxia in the donor tissue are unavoidable facts during the transplantation 
process, with all the negative effects associated with them and the successive reperfusion are 
necessary in the situation during the transplantation process, a reduction of deleterious effects 
in this state are desirable. Due to many inventions and studies in the field of transplantation 
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medicine more and more factors, that have great influence during the surgical procedure, are 
revealed.  
The role of HIF-1 which is described above seems to be of great importance in this process 
especially with a view on one of its transcription products, VEGF. Together with other 
proinflammatory gene products, induced via HIF-1, the suggestion rises up, that an inhibition 
of HIF-1 in the early acute phase of inflammatory reaction in the transplanted graft can lead to 
a benefit. Using a clinic-near animal model of orthotopic lung transplantation which had to be 
established and modified in the beginning, the investigation of the role of HIF-1 and its tran-
scription products, especially VEGF, is the main interest in this work with the focus on fol-
lowing questions: 
 
 What role does HIF-1 play in the lung during ischemia and in the transplanted lung? 
 
 Which gene products of HIF-1 are involved during ischemia and in the transplanted 
lung? 
 
 Is it possible to influence HIF-1 pharmacologically to get a benefit for the transplanted 
lung? 
 
 What influence does HIF-1 have on the short-term survival after lung transplantation? 
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2 Materials and Methods 
The following chapter comprises all methods that were applied in the presented work includ-
ing new or modified ones. All used materials are listed in the addendum in 8.1.  
 
2.1 Methods 
2.1.1 Design of the Experiment 
The experiment was divided into three parts: 
The first part is set out to determine the appropriate Deguelin concentration for effective HIF-
1 inhibition via a cell assay(2.1.2). In the second part, the functionality of Deguelin in vivo is 
tested in a pilot experiment on rat lungs (2.1.3). The establishment of the surgery method 
(3.1) and the observation of Deguelin in vivo during lung transplantation is the third part 
(2.1.4).  
 
2.1.2 Cell Culture 
Due to the data known about the rotenoids, it was essential to start the experiments in in vitro 
cultivated cell lines to ensure no great toxicity to the living cell. As we used commercially 
available cell lines (HMEC-1 and HTB-177), no isolation was necessary. Cells are normally 
cultivated and maintained in standardized condition at defined temperature in a appropriate 
gas mixture, normally 37 °C and 5% CO2 for mammalian cells. The conditions vary from the 
different types of cells but should normally be done as described in the manufacturer’s proto-
col for commercial available cell lines. Most commercially used cell lines are immortalized, 
which gives them great benefit as the limit of a cell passage is not as that dramatic as in non-
immortalized cell lines which can often not be used more than seven times. The cell passage 
is a necessary step for the cultivation and normally 2-3 passages are done before cells are used 
for the experiment to let them recover from the frozen storage state.  
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2.1.2.1 Cultivation 
Human Microvascular Endothelial Cells (HMEC-1) 
Human microvascular endothelial cells (HMEC-1) were thawed and cultivated after manufac-
turers protocol in 250 cm² flasks with complete growth medium for HMEC-1 (Table 2) until 
they reached a confluence of 80%. Medium was changed 3 times per week. For passage, cells 
were washed with 10 ml sterile PBS and detached with 5ml Accutase at 37°C in an incubator 
with 2% O2, 5% CO2 until the cells were completely floating. The cell suspension was split 
1:3 or maximum 1:5 and transferred with 15-20 ml new medium in a new flask.  
For seeding in 6 cm petri dishes for experimental part, cells were harvested as described pre-
viously. After centrifugation at 300 x g for 5 minutes, the supernatant was discarded. The cell-
pellet was resuspended in 5 ml new medium and the suspension was diluted 1:10 with 
Trypan-blue and counted using a Neubauer-counting chamber. Then 200,000 cells were seed-
ed in each petri-dish and cultivated until they reached a confluence of 80%.  
 
Table 2: Ingredients of used Growth Medium for HMEC-1 cells 
HMEC-1 Complete Growth Medium 
Substance Concentration volume 
MCDB 131 without L-Glutamin 500 ml  500 ml  
Epidermal Growth Factor (EGF)  5µg/500ml 250 µl 
Hydrocortison  500µg/ml 100 µl 
Penicillin/Streptavidin solution 1% 5 ml  
 
 Human Lung Epithelial Cells (HTB-177) 
Human immortalized lung epithelial cells (HTB-177) were thawed and cultivated after manu-
facturers protocol in 250 cm² flasks with complete growth medium for HTB-177 (Table 3) 
until they reached a confluence of not more than 80%. Medium was changed every second 
day and for passage cells were washed with 10 ml PBS and detached with 5 ml Trypsin + 
EDTA and incubated at 37°C with 2% O2, 5% CO2 until all cells were floating. Cells were 
centrifuged at 500 x g for 5 min and the supernatant was discarded. The pellet was resuspend-
ed in 5 ml medium and split 1: 3 or maximum 1:8 and put in 15-20 ml of new medium in a 
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new flask for passage. For the experiment cells were counted as described previously and 
200.000 cells were seeded in 6 cm petri dishes.  
 
Table 3: Ingredients for used Growth Medium for HTB-177 cells 
HTB-177 Complete Growth Medium 
Substance Concentration volume 
RPMI1640 Medium 500 ml  500 ml  
Fetal calve serum (FCS) 10 % 50 ml 
 
 
2.1.2.2  Cell Culture Experiments 
Deguelin was solubilised in DMSO at an end-concentration of 4 mg/ml. From this stock, three 
stock dilutions were made for cell culture experiments: 10 mM, 100 µM and 10 µM. 
Both cell lines were treated with different concentrations of Deguelin in DMSO (1 nM, 
10 nM, 100 nM) for 12 h prior to hypoxia and the medium was equilibrated in the hypoxia 
chamber 24 h before experiment at 2% O2, 5% CO2 at 37°C. Then, the equilibrated medium 
with the Deguelin-concentrations was added under hypoxic conditions and cells were exposed 
to hypoxia for 6 h and then harvested. The best hypoxic time was detected via pre-
experimental test in the hypoxic chamber by incubating cells under hypoxic conditions and 
harvesting after 2 h, 4 h, 6 h, 8 h, 12 h, 16 h and 24 h – the most effective inhibition was ob-
served in cells incubated for 6 h under hypoxic conditions. Cells were grouped as shown in 
Table 4.  
 
Table 4: Scheme of cell culture experiment 
Normoxia 
No treatment, harvest at the endpoint of the experiment 
 
Hypoxia SHAM DMSO Deguelin in DMSO (12h pretreatment) 
6h hypoxia 
+ hypoxic me-
dium 
No treatment 1 µM 
 
1 nM 10 nM 100 nM 
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2.1.3 Pilot experiment in vivo 
Next, the effect of Deguelin on HIF-1α and the ischemic lung was tested in vivo after deter-
mination of a therapeutically effective dose of 100 nM from cell culture experiments. 
 After this, lungs of rats were harvested as described in the donor-procedure and left under 
ischemic conditions at 37°C for one hour. Three groups were build in which the effect of 
warm ischemia with no treatment, warm ischemia with previously 3 d treatment of Deguelin 
and a non-treated, non ischemic sham group was examined. To reduce the number of animals 
that were necessary, statistical significance was determined and reached at a number of 6 an-
imals. 
 
Table 5: Summary of groups in the pilot experiment. 
 
 
Group Size Treatment Ischemic conditions 
n=6 Deguelin for 3 d warm ischemia for 1 h 
n=6 untreated warm ischemia for 1 h 
n=6 untreated no ischemia (sham) 
Figure 6: Schematical design of the Pilot experiment. The red bolts represent the ischemia at 37°C.  
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2.1.4 Main Experiment in vivo 
The second step of the experiment was the examination of the inhibitory effect of Deguelin 
under the condition of a complete lung transplantation and the outcome after an observation 
period of 2  d post operation. Therefore, animals were divided in donor and recipients and the 
donor was treated 3 d before surgery with the described dose of Deguelin and recipients were 
also treated 2 d after surgery. Another group of donor and recipients was build in which also 
lungs were transplanted without any further medical treatment. 
 
Table 6: Summary of groups in the main experiment. 
Group Size Treatment Animal 
n=6 Deguelin for 3 d preoperative donor 
Deguelin for 3 d preoperative + 2 d postop-
erative 
recipient 
n=12 untreated controls (donor + recipient) 
 
 
Figure 7: Schematical Design of the main experiment. The two bolts in red and blue symbolize the 
two ischemia-periods of cold and warm ischemia in the transplantation process.  
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2.1.5 Animals  
The study was approved by the Animal Care and Use Committee of the state of Hesse 
(Regierungspräsidium Darmstadt), Darmstadt, Germany (V54-19c20/15-F91/56). Surgery and 
animal care were performed in accordance with the „Guide for the care and use of laboratory 
animals“ (National Institutes of Health, volume 25, no. 28, revised 1996), EU Directive 
86/609 EEC and German Protection of Animals Act. Male Sprague Dawley rats (SD, Janvier, 
St. Berthevin, France) weighing 225-250 g were housed in the central research establishment 
of the Goethe-University Frankfurt. At the beginning of the experiment rats were randomized 
to form pairs of donor and recipient rats which were kept together in approved plastic cages (2 
animals per cage), had water and food ad libitum and were housed in rooms equipped with a 
12 h light cycle. Rats were individualized by a numeral code labeled onto the tail with water-
resistant paint.  
 
2.1.6 Deguelin Treatment of the Animals 
For treatment with the HIF-1α inhibitor Deguelin, a stock solution in 100% DMSO was made 
from the crystalline form at 25 mg/ml and stored at – 20°C for further use. For the application 
of Deguelin to the animals, the stock solution was dissolved in corn oil at a final concentra-
tion of 10 mg/ml. Deguelin was applied via gavage at a dose of 4 mg/kg adapted to the indi-
vidual bodyweight twice a day. Treatment started 3 d before lung transplantation in recipients 
and donors and ended 2 d after transplantation (recipients). 
 
2.1.7 Orthotope left Lung Transplantation 
To establish the method of the orthotope left lung transplantation, we first used a method, that 
is described earlier by Zhai et al
226
 and leads back to the method of Mizuta et al
227
 who in-
vented the cuff-technique for the lung transplantation. The method of Zhai, which is used for 
our first group, is shortly described here and the modified method by our group is described in 
3.1. The left lung lobe of the donor animal is harvested by removing the heart-lung package 
after perfusion over the Vena cava caudalis and the three important structures of artery, vein 
and bronchus are primed free from all surrounding connective tissue, so all structures are 
clearly visible. Cuffs are prepared after Zhai’s method as shown in Figure 13 and all three 
structures are fixed to a cuff without any tail. The single left lung lobe is stored at 4°C until 
the recipient is ready for transplantation. Via a left thoracotomy the recipient’s left lung lobe 
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is moved out of the body and the three structures are clamped with microaneurysm clips. Af-
ter the blood flow is arrested, the structures are incised and the structures of the donor lung 
are placed into the structures of the recipient by holding on to the cuff. Once in place, a thread 
is fastened around and the Cuff and the clamps are shortly removed to prove if the blood flow 
can be restored or if there is any obstruction left. After this, the clamps are removed complete-
ly and the connection to the recipients left lung is carefully cut. The lung is now removed 
back into the thoracic cavern and the thorax is closed.  
For establishment of the method, some animals were transplanted as described above and 
then, transplanted with the modified method described in 3.1. The animals that had undergone 
this kind of surgery (n = 11) were compared with animals, that were operated by the modified 
method (n =11).  
 
2.1.8  Wet-to-Dry Ratio 
 To analyse the dimension of lung edema between the different groups, the method of Wet-to-
Dry ratio is used. A part from the collected lung sample is put into a previously weighted 2 ml 
Eppendorf tube of which the lid is perforated and the gained data is recorded. Then the tube is 
weighted again to get the weight of the ‘wet’ lung sample. To dry the sample, the tube is 
placed in an oven for 72 h at 60°C and the new weight of the tube is again recorded. By divid-
ing the wet-weight by the dry-weight a ratio is calculated and compared. Based on this data, 
the ratio of previous and actual weight give an idea of the volume of water content in the tis-
sue and therefore of the dimension of lung edema.  
 
2.1.9 Histology 
To examine structural changes in tissue, histology is the method of choice. For this method, 
thin slices of fixated tissue, normally about 3-5 µm, are microscope slides, heat fixated and 
stained and at last covered with a cover glass. The thus prepared tissue can now be examined 
under the microscope and, depending on the staining, evaluated. The advantage of this meth-
od is that all aspects of the tissue can be examined in the same appearance as they were in the 
organism. This gives the chance to not only to observe the mere structure of tissue, but also to 
mark different proteins or genes of interest by special immunological staining methods and 
examine them not only in their quantity but also in their location in the tissue.  
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2.1.9.1 Fixation of the Samples 
From all harvested lungs, half of each lung lobe is fixated for histological use. The fixation of 
fresh harvested samples is essential for storage and further preparation processing; it stabilizes 
samples and avoids bacterial and fungal growth. Normally, aldehydes, mostly formaldehyde 
or its polymerized form paraformaldehyde, are used for fixation right after harvesting. For-
maldehydes are so called cross linking fixatives which create covalent chemical bonds be-
tween the proteins and last long enough so that the fixation reagent can immerse deep enough 
inside the tissue samples. It should not be applied longer than necessary to avoid tissue dam-
age. For the harvested rat lungs 8-12 h are used (rule-of-thumb: immersion speed of 1 mm per 
1 h). Formaldehyde is used in a 4 % solution in PBS and afterwards, the samples are put in 
fresh PBS over 24 h. After this samples are dehydrated in different concentrations of alcohol, 
beginning in a low concetration and ending in pure alcohol. For the last dehydration step, 
methylbenzoat is used to make sure that the tissue is best prepared for the following contact 
with the paraffin. Before embedding the tissue, the samples are washed in three steps in liquid 
paraffin, that is heated and then left in the last bottle of paraffin in the oven at not more than 
60 °C over 16 h (Table 7). 
 
Table 7: Fixation and embedding scheme. 
step reagent time 
Fixation 
1 Formaldehyde 4% in PBS 8-12 h 
Dehydration 
2 PBS (phosphate-buffered saline) 24 h 
3 Ethanol 70% 1 h 
4 Ethanol 80% 1 h 
5 Ethanol 90% 1 h 
6 Ethanol absolute 1 h 
7 Methylbenzoat I 8 h 
8 Methylbenzoat II 16 h 
Paraffin treatment  
9 Liquid paraffin (56-58°C) 3x 5 min 
10 Liquid paraffin (56-58°C) 16 h 
 
2.1.9.2 Embedding 
Tissue Samples are embedded after paraffination with the embedding machine in metal his-
tology molds and quickly cooled down on ice until the paraffin completely hardened.   
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2.1.9.3 Cutting  
For all Samples, 6 slides are cut, for immunostaining on Super Frost Plus Slides and on 
Süssefrost slides for H&E staining. A Leica microtome is used and all cuts had a thickness of 
4 µm. The cuts are carefully shoved on the slide and the paraffin is smoothened in a waterbath 
with a temperature of 40 °C. Afterwards slides are drained and then, the tissue cuts are fixed 
on the slide via heat for 30 min at 60 °C in the oven.  
 
2.1.9.4 H&E staining 
The Hematoxylin – Eosin staining is a common dye in histology and gives a good overview 
over the tissue. The used Mayer’s Hematoxyline belongs to the aluminium-hematoxylin-
solutions that are also known as ‘haemalum’, which refers to the fact that an oxidative form of 
hematoxylin, the haematein, combines with the aluminium ions. Under alcoholic acidic condi-
tions in its complex with aluminium, it is more soluble and appears in a dark red color and 
turns blue and less soluble under aqueous neutral or alkaline conditions. Aluminium-hematein 
is said to bind basophilic structures, which means in this case, that it binds to acidic moieties 
like phosphate groups (nucleid acid) of the DNA backbone. It is normally used to stain nuclei 
and it also stains some other materials as keratohyaline granules and calcified deposit.  
Normally, after the staining of the tissue, a so called ‘blueing’ follows – in this step, the 
stained tissue is put in tap water to turn the color of the hematein into blue due to the more 
alkaline conditions of harder tap water than distilled water.  
The Eosin-G (or Eosin-Y) is one of two derivates of fluorescein. It is used as a counterstain to 
hematoxylin and is acidic, so that stains basic structures such as cytoplasma in a more or less 
intense pink and red blood cells intensely red. To intense the dye, acetic acid can be added.  
For the staining, the slides are hydrated in different alcohol concentrations and water. After 
removing excess water, slides are stained in Mayers hematoxylin for 3 min and afterwards 
shortly dunked in 0.1 % HCl-solution. Now follows the ‘blueing’ in running tab-water avoid-
ing the water jet to get directly in contact with the tissue slides. The procedure should be con-
tinued until the wished intensity of blue is reached. After this, slides are shortly left in dis-
tilled water and again excess water is removed before staining with Eosin-Y for 3 min. Excess 
eosin is removed before the slides are rehydrated in alcohol again (Table 8). After the last 
dehydration step, the slides are fixated with DPX-glue under a cover glass and dried.  
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Table 8: Histological staining scheme. 
Step Reagent Time 
Rehydration/Deparrafination 
1 Xylol 100% 10 min 
Xylol 100% 10 min 
2 
 
Ethanol 100% 5 min 
Ethanol 100% 5 min 
3 Ethanol 96% 10 min 
4 Ethanol 70 % 10 min 
5 Ethanol 50 % 10 min 
6 Destilled water 5  min 
Nucleus staining  
7 Mayers-hematoxylin 3 min 
8 0.1 % HCl 2 sec 
9 Blueing under running tab-water 5-15 min 
10 Distilled water 1 min 
Counterstaining 
11 Eosin-Y (+ concentrated acetic acid 
) 
200 ml (+ 400 µl ) 
3 min 
Dehydration 
12 Ethanol 70 % 5 min 
13 Ethanol 96 % 5 min 
14 Ethanol 100 % 5 min 
Ethanol 100 % 5 min 
15 Xylol 100 % 5 min 
Xylol 100 % 5 min 
Fixation with DPX under cover glass 
 
Materials and Methods 
 
35 
2.1.9.5 Immunostaining  
As the name implies, immunohistochemistry works with a staining via immunoglobulin that 
bind to a specific structure in the tissue. Similar to the Westernblot, a primary and a secondary 
antibody is used. Whereas the primary antibody binds directly to the target, the secondary 
antibody normally bears an enzyme which is capable of catalyzing a reaction producing a 
colored product. This is normally a peroxidase or a alkaline phosphatase.  
For our immunhistochemistry, Superfrost Plus slides are used, to avoid the sample slices to 
detach during the preparation steps. Dehydration is done as described for the H&E staining 
and after the slides are put in PBS or TBS for 5 minutes.  
To expose the epitopes, slides are put in a heat-resistant cuvette and covered with unmasking 
solution. They are heated in the microwave at 600-700 W and evaporating liquid is filled up 
every 5 minutes so the slides are always covered. The time depends on the epitope and lies 
between 5-10 min.  
After heating, the hot cuvette is taken out of the microwave and let cool down to room tem-
perature.  
If slides have cooled down, they are washed in TBS-T two times for 5 minutes.  
A ‘wet-chamber’ is prepared for further steps: 
Therefore a common ice box is used which is coated with two layers of paper towel and 
soaked with water to prepare the ‘wet chamber’.  
Now several steps of washing and blocking are done, before the primary antibody can be add-
ed. If a biotinylated secondary antibody is used, all steps are performed, if a HRP labeled an-
tibody is used, only steps 4-7 are performed.(Table 11)  
One of the tissue slices has always to be free of primary antibody as a control for the selectivi-
ty of the secondary antibody and proof of background staining. The slices are surrounded with 
a hydrophobic barrier pen as shown in the scheme below. Then the barrier density is tested by 
covering the slice with TBS-T or PBS (Figure 8).  
Materials and Methods 
 
36 
 
Figure 8: Schematical depiction of an immunohistochemical slide. 
 
Buffer solutions: 
 
Avidin blocking solution 
1000 µl        0.1% TBS-T or PBS 
 100  µl        serum from the species of the secondary antibody  
 4 drops       Avidin blocking reagent from Avidin-Biotin blocking kit  
 
Biotin blocking solution 
1000 µl       0.1% TBS-T or PBS 
 100 µl       serum from the species of the secondary antibody 
4 drops       Biotin blocking reagent from Avidin-Biotin blocking kit 
 
Blocking buffer 
1000 µl       0.1% TBS-T or PBS 
 100 µl       serum from the species of the secondary antibody 
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Antibody solutions 
The best concentration is tested before staining with one slide for every antibody used. All 
antibodies are diluted in blocking buffer. ( 
Table 9) 
 
Table 9: List of used primary antibodies 
 Primary Antibody 
Antigen Description Dilu-
tion Name Produced in Reactiv-
ity 
Manufac-
turer clonality 
CD163 Mouse anti Rat CD 
163 
MCA342R 
mouse rat AbD Serotec 1:300 
monoclonal 
ICAM-1 Mouse anti Rat 
ICAM-1 
LS-C45355 
mouse rat LSBio 1:300 
monoclonal 
CXCR4 Rabbit anti rat 
CXCR4  
Ab2074 
rabbit rat abcam 1:300 
polyclonal 
CD 68 Mouse anti rat CD 68 mouse rat CHEMICO
N 
International 
1:300 
monoclonal 
Macro-
phage/De
ndritic 
cells 
Macrophage/Dendritic 
cells Antigen 
ABIN 289947 
mouse rat Antibodies – 
online 
GmbH  
1:300 
monoclonal 
 
Secondary antibodies are used for biotinylated antibodies from the Elite ABC-Kits in follow-
ing concentration: 
1000 µl         blocking buffer 
    10 µl         secondary antibody from Kit   
 
Following Kit is used for the detection of CXCR-4 antibody: 
Vectastain Elite ABC Kit       Rabbit IgG 
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The following secondary antibody is used for the detection of CD 163, CD 68 and ICAM-1 ( 
Table 10): 
 
Table 10: List of used secondary antibodies 
Secondary Antibody 
Antigen Description dilution 
Name Produced 
in 
reactivity manufacturer 
clonality 
Anti Mouse Goat anti mouse HRP la-
belled 
PO447 
Goat mouse DAKO 1:300 
 
 
 
 
ABC-Solution: 
For biotinylated antibodies, signals are enhanced by using the Vectastain-elite ABC kits. 
ABC-solution is prepared after manufacturers protocol. 
ABC solution is prepared on the day of use and has to incubate 30 minutes before use. It  
is gently shaken during the 30 minutes.  
 
DAB-solution: 
Vectastain-DAB kit is used and DAB is prepared after manufacturer’s protocol. It is prepared 
directly before use. 
 
Table 11: Summary of immunohistochemical procedure. 
Step Procedure Time 
Day 1 
Avidin-Block 
1 Cover all slides with Avidin-blocking solution and incubate at room tempera-
ture 
1h  
Washing step 
2 Tip off the liquid and wash slides in fresh 0.1% TBS-T  5 min 
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Step Procedure Time 
Biotin-Block 
3 Cover all slides with Biotin-blocking solution and incubate at room tempera-
ture 
1h 
Washing step 
4 Tip off the liquid and wash slides in fresh 0.1% TBS-T 5 min 
Peroxidase-Block 
5 Cover all slides with freshly prepared 6% H2O2  and incubate at room tempera-
ture 
30 min 
Washing step 
6 Tip off the liquid and wash slides in fresh 0.1% TBS-T  5 min 
Primary antibody  
7  Cover only two of three slides with the Primary antibody solution; incubate 
like it is said in the datasheet, the most save is over night at 4 °C  
2 – 16 h 
(overnight)  
Day 2 
Washing step 
8 Tip off the liquid and wash slides in fresh 0.1% TBS-T  5 min 
Secondary antibody 
9 Cover all slides with secondary antibody solution and incubate at room tem-
perature 
1 h  
Washing step 
10 Tip off the liquid and wash slides in fresh 0.1% TBS-T  5 min 
ABC-solution 
11 ABC-solution should be prepared in the last 30 min of antibody solution and a 
small rest should be saved to test the ABC-DAB reaction. Cover all slides and 
incubate at room temperature 
30 min 
Washing step 
12 Tip off the liquid and wash slides in fresh 0.1% TBS-T  5 min 
DAB-reaction 
13 Incubate with DAB at room temperature until the tone of brown is adequate – 
the negative control stays in a slight pink (depending on the DAB used) or 
colorless 
5-7 min 
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Step Procedure Time 
Stop of DAB reaction 
14 DAB reaction is stopped by putting the slides in fresh distilled water 5 min 
Counterstaining with hematoxylin 
15 Hematoxylin is diluted with water 1:1 and directly put on the slices 10 min                                                                  
Washing step and blueing  
16 slides were shortly washed in distilled water and then blued like described for 
the H&E stain and reaction is stopped when the adequate blue-tone is reached 
10 min 
Fixation under cover glass with Roti-Mount Aqua  without dehydration or with DPX after dehydration 
as described for H&E stain 
 
2.1.9.6 Cell Count for Immunohistochemical Staining 
To compare the slides of the stain and to reduce inaccuracy due to different intensities of the 
individual stains and tissue-non tissue ratio, the counting is done by a program code gratefully 
written for our group by Dr. Dipl. Phys. Scheller from the Clinics for Anesthesiology, Inten-
sive care and Pain management.  
Therefore, pictures are set in the three dimensional RGB (Red Green Blue) room with m x n 
pixels x 3 color layers. The benefit of this is that the matrix consists of the three layers for 
different colors that are divided into red, green and blue. By additive effects, the complex 
colors in a picture are presented and every pixel can have a value from 0-255.  
This definition brings the benefit of not only being able to differentiate stained (brown) from 
unstained (blue) tissue, but also to measure the intensity of the brown and blue tissue and set 
it into relation. Furthermore, a miscalculation by adding the non – tissue area (white) can be 
avoided. 
Pictures are loaded into Matlab with the Image Processing Toolbox as RGB color figures (8-
bit depth, figure size 1944x2592 pixels). For each of the color matrices red, green and blue, 
pixel values are determined. Alveoli are determined, when the pixel value of the matrix cod-
ing for reed exceeded 0, the color brown is defined as a difference value between pixel values 
of blue and green not exceeding a value of 12 and, conditionally values in the matrix coding 
the color reed not exceeding a value of 80. All other combinations of pixel values are classi-
fied as tissue not stained in colors of brown. Results show the relative areas of areas stained in 
shadows of brown to the rest of the tissue with the area of alveoli subtracted. 
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2.1.10 Western Blot 
 
2.1.10.1 Homogenization and Preparation of Tissue Samples 
Samples are snap-frozen in liquid nitrogen and stored at -80°C until further use. To avoid 
thawing, they are kept in liquid nitrogen right before use and all steps are carried out on dry 
ice.  
2.0 ml Eppendorf tubes are weighted and precooled on dry ice. A dry ice block is wrapped in 
clean aluminium foil and disinfected. The forceps to hold the sample is sterilized and put in 
80% alcohol solution and a disposable scalpel is used. All instruments are cleaned after every 
sample, disinfected in alcohol and precooled on dry ice.  
The frozen sample is carefully cut in small pieces and put in the 2.0 ml Eppendorf tube to be 
weight quickly so that it doesn’t thaw. 1 ml of Frackelton-Lysis buffer (Table 12) is added to 
50-100 mg of tissue. The tissue-buffer mixture is homogenized with an Ultraturrax until no 
big pieces are left and the mass has turned completely homogen.  
The homogenized sample-buffer mixture is centrifuged at 15000 rpm for 10 min at 4°C. The 
supernatant is transferred to a new, precooled Eppendorf tube, without touching the pellet. To 
avoid freeze and thaw cycles, the supernatant is aliquoted in smaller Eppendorf tubes for fur-
ther use. 
 
Cell samples. To avoid degradation of HIF-1α, cells are directly harvested in the hypoxia 
chamber. The hypoxic medium is removed and the cell layer is briefly washed with 2 ml cold 
PBS. PBS is again removed and 100 µl of the Urease-buffer for HIF-1α (Table 12) is put on 
the cells. The cell layer is then removed with a disposal cell scraper and the buffer-cell mix is 
transferred into a 1.5 ml Eppendorf tube and put on ice.  
The cell-buffer mixture is incubated on ice for 10 min and then sonificated with 5 pulses and 
centrifugated afterwards at 16 000 g for 20 min at 4 °C. The supernatant is transferred into a 
new Eppendorf-tube.  
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Table 12: Buffers used for sample homogenization and preparation  
Urea Lysis Buffer (100 ml)  
Frackelton Lysis Buffer (100 ml) 
Volume  Substance Concentration Volume  Substance Concentration 
50 ml   Urea 6,65 M  0.121 g  Tris 10 mM 
10 ml  Glycerol 10 % 1.338 g  Natriumpyro-
phosphate   
30 mM 
5 ml  SDS (SDS 20%) 1 % 0.292 g  NaCl 50 mM 
1 ml   Tris/HCl (1M) 
pH 6.8 
10 mM Set pH to 7.05 
Add immediately before use 1 ml  Triton X-
100 
1 % 
 DTT (1M stock) 1mM Add immediately before use 
40 µl/ml  Protease Inhibi-
tor Cocktail 25x 
1x 10 µl/ml   PMSF 
(100mM 
stock) 
1 mM 
10 ml/ml  Natrium-
vanadate 
(10mM stock) 
100 µM 
40 µl/ml  Protease Inhi-
bitor Cocktail 
25x 
1 x 
 
 
2.1.10.2 Protein Measure 
Protein mass is measured via colorimetric protein assay. Two different methods are used: The 
Bradford assay and the bicinchoninic acid protein assay (BCA). The last one has to be used 
for the samples that contained Urea buffer as it leads to an unwanted color change in the 
Bradford assay.  
 
Bradford Assay. This assay works with the dye Coomassie Brilliant Blue G-250, which ap-
pears red and turns to blue depending on acidic conditions. When it binds to the amino acids 
of the protein in its red state, it donates its free electron pair to the ionizable functionalities of 
the protein, thereby disrupting the proteins native conformation. Thus, the hydrophobic pock-
ets are exposed and can non-covalently interact via van der Waals forces with the non-polar 
regions of the dye This stabilizes the blue form, which can be measured via absorbance read-
ing.  
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The Bradford assay is linear at low protein concentrations, normally between 0 µg/ml to 
2000 µg/ml, therefore, the samples are diluted 1:5 (2 µl sample + 8 µl buffer) for the cell-
samples and 1:25 (5 µl sample + 120 µl buffer) for the tissue-samples.  
As a standard, different dilutions of BSA in water are prepared (0 – 1000 µg/ml) and 10 µl of 
each standard and sample are pipetted  in a microplate in duplets. Then all slots are filled up 
to 200 µl with Bradford solution. The plate is covered with a lid or parafilm and incubated for 
5 minutes. The absorbance is read out at 595 nm in a photospectrometer. 
 
BCA Assay. For the BCA assay the BCA Kit from Pierce is used. This assay relies mainly on 
two interactions: in a temperature-dependent reaction, Cu²
+ 
ions from the cupric sulphate in 
the BCA reagent are reduced to Cu
1+
 ions via the peptide bonds of proteins. Then two mole-
cules of bicinchoninic acid chelate with one Cu
1+
 ion and the formally green solution turns 
purple. This purple product absorbs light strongly at a wavelength of 562 nm. For minimizing 
unequal amino acid composition, the assay is incubated at a temperature of 37°C.  
All samples measured in BCA assay are diluted 1:10 and a BSA standard is used, equally to 
the one for Bradford assay. 10 µl of each sample and standard are pipetted in duplets in a 
microplate.  
The reagents of the kit are mixed as discribed in the manufacturers protocol (1 ml reagent A + 
20 µl reagent B) and 200 µl of the BCA solution is added to all samples and standard. Then 
the microplate is covered with a lid or parafilm and incubated at 37°C for 5-10 minutes. 
Measurement is done when the reaction turned purple. The absorbance is read out at 562 nm 
in a photospectrometer. 
 
2.1.10.3 Preparation for Blotting 
For tissue samples, 30 µg are loaded and 4 µl of loading buffer (Table 13) are added and all 
samples are filled up to 16 µl with water. For cell samples, 100 µg are loaded and 4 µl loading 
buffer are added. All samples are filled up to 16 µl with water.  
Proteins are denaturized at 95°C for 5 min. 
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Table 13:  Used Loading Buffer 
Loading Buffer (10 ml) 
Volume substance 
6 ml  deionized water 
1 ml  500 mM Tris-HCl pH 6,8 
2 ml  Glycerol 
1g  SDS 
50 mg  Bromophenolblue 
(0,05%) 
Add just before use 
1 ml  ß-Mercaptoethanol 
 
 
SDS-PAGE. The Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is 
a common method for separating denaturized proteins by molecular weight. Depending on the 
size of the proteins, we use 10% (HIF-1α) or 15% (VEGF) gels (Table 14,Table 15) for de-
tection. First, separating or stacking buffer (Table 16) is mixed with water and the acryla-
mide. Polymerization is induced by adding ammoniumpersulfate (APS) and TEMED directly 
before use. The gels are polymerized in a gel caster starting with the separating gel which is 
polymerized for at least 30 min. To avoid drying and to get a smooth surface, isopropanol is 
put on top of the polymerizing gel. Then, the isopropanol is tipped and the stacking gel is 
filled right to the line of the gel chamber. The comb with 10 wells is carefully put into the still 
liquid gel and the gel is polymerized. It is then incubated overnight at 4°C in a wet chamber 
and used the next day.  
 
 Table 14: Used Separating Gel 
Separating Gel (volume for two gels) 
Density 30% Acrylamide Separating 
Buffer 
Distilled water 10% APS TEMED 
10 % 6.65 ml  5.4 ml 7.95 ml 100 µl 80 µl 
15 % 10.0 ml 5.4 ml 9.6 ml 100 µl 80 µl 
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Table 15: Stacking Gel  
Stacking Gel (volume for two gels) 
Density 30% Acrylamide Loading 
Buffer 
Distilled water 10% APS TEMED 
5 % 2.5 ml 3.8 ml 8.7 ml 60 µl 20 µl 
 
Table 16: Buffers used for SDS-PAGE  
Separating Buffer (200 ml) Stacking Buffer (200 ml) 
Volume Substance Concentration 
Volume 
Substance Concentra-
tion 
45.4g  
Sigma 7-
9 
1.875 M 
15.1 g  
 
Sigma 7-9 0.625 M 
1 g  
 
SDS 0.5 % 
1 g  
 
SDS 0.5 % 
Fill up to 200 ml with deionised water Fill up to 200 ml with deionised water 
Set to pH 8.8 
Set to pH 6.8 
 
Running Buffer (1l) Transfer Buffer (1l) 
Volume Substance Concentra-
tion 
Volume 
Substance Concentra-
tion 
3 g  
 
Sigma 7.9 50 mM 
3 g  
 
Sigma 7-9 25 mM 
14.4 g  
 
Glycine 0.384 M 
14.4g  
 
Glycine  
1 g  SDS 0.1 % 
800 ml 
distilled water 
Fill up to 1l with deionised water 
200 ml  
 
Methanol 
 
 
For Detection of the protein, a sodium dodecyl sulphate (SDS) polyacrylamid gel electropho-
resis (SDS-PAGE) is used. SDS-PAGE is a method that works with the denaturated variants 
of the protein and separates them by their molecular weight. To reach adequate denaturation, 
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a strong reducing agent – the loading buffer – is added to each sample and by short heating, 
this effect is enhanced. It removes tertiary and secondary structures, as for example disulfide 
bonds which are reduced to sulfhydryl groups. So prepared, the sample proteins become cov-
ered in the negative SDS and move to the positive charged electrode along the gel through the 
mesh of acrylamide by applied voltage on the gel that lets the protein run in different speed. 
Depending on the concentration of the mesh of acrylamide, smaller proteins can run through 
the gel better than bigger ones. Thus, high concentration of acrylamide are more suitable for 
detection of lower molecular weight proteins. High molecular weight proteins need low 
acrylamide concentrations. If bands are not adequately separated, or bands have run through 
the gel, the acrylamide concentration has to be adapted.  
To get an overview over the progress of the running proteins, markers are used – a commer-
cially available mixture of proteins – in this case, one which generates colored bands, and 
another, which is only visible under UV-light after luminol-treatment.  
Using a biorad - MINI PROTEAN CELL 3 the earlier prepared gels were loaded with the 
samples and 5 µl SPECTRA Brood Range visible marker in the first slot and 5µl Magic 
Marker in the last slot. After filling the chamber with running buffer (Table 16) and prove if 
it does not leak, the gel runs at 80 volt for the first 30 minutes through the stacking gel and 
then for 60 minutes at 120 volt through the separating gel.  
 
2.1.10.4 Protein-Transfer and Detection 
For the detection of the proteins by antibodies, they first have to be transferred onto a mem-
brane. This membrane normally is made of nitrocecullose or polyvilidene difluoride (PVDF). 
The membrane has to be placed on top of the gel and a varying number of filter papers and 
sponges are placed around it, depending on the manufacturer’s protocol. Using a defined elec-
trical potential, the proteins move from the gel to membrane and appear in the same bands as 
they were in the gel and are now on the surface of the membrane and ready for detection. 
So after the run, the gel is carefully removed from the cassette and put on a prepared construc-
tion of one sponge and two filter papers which are soaked in transfer buffer (Table 16) and a 
nitrocellulose membrane is put on the gel. Then it is again covered with filter papers and a 
sponge and the transfer cassette is put in transfer buffer and the transfer is peformed at 4 °C 
for 1 ½ hours at 100 volt. After this, the success of the blot is proved by a short staining with 
Ponceau Red.  
 
Materials and Methods 
 
47 
Table 17 Buffers for Protein Detection 
PBS stock solution (10 x) TBS stock solution (10x) 
Volume Substance Concentration Volume Substance Concentration 
80 g NaCl 1.37 M 80 g  NaCl  1.37 M 
11.5 g  Na2HPO4 (waterfree) 81 mM 12.1 g Tris-base 100 mM Tris-
HCl 
2 g  KCl 27 mM Ad 900 ml aqua bidest. 
2 g KH2PO4 (waterfree) 14.7 mM Set pH on 7.3 with HCl  
Ad 1 l aqua bidest. 
PBS (1x) 1 l TBS (1x) 1l 
Volume Substance volume substance 
100 ml PBS-Stock solution (10x) 100 ml TBS-stock solution (10x) 
900 ml Aqua bidest. 900 ml Aqua bidest. 
Blocking solution (BSA 5 %) Washing buffer (1l) (TBS-T 0.1 %) 
100 ml TBS - T  (1x) 1 l  TBS (1x) 
5 g BSA  5 % 1 ml  TWEEN 0.1 % 
 
After washing off the Ponceau Red in 0.1 % TBS-T (Table 17) the Membrane is put into a 
solution of blocking solution for two hours to block non-specific binding. Then the primary 
antibody (Table 18) in a tested dilution in blocking solution (Table 17) is put on the mem-
brane and incubated overnight at 4 °C. The next day, the membrane is washed in washing 
buffer shortly for 3 mins, then 2 x 5 mins, 1 x 10 mins and 1 x 30 mins – afterwards the sec-
ondary antibody (Table 18) in its tested dilution in blocking solution is put on and incubated 
at room temperature for one hour. Then again, the membrane is washed as described previ-
ously.  
For imaging, the chemiluminescence-reaction of luminol with the horseradish-peroxidase 
(HRP) of the HRP-labeled second antibody, is used. Luminol is a chemiluminescent dye 
which must be activated first, to exhibit luminescence. This is normally reached by an oxidant 
as peroxides. The picture is taken with a Kodak Imager and analysed with ImageJ Software. 
As control, ß-Actin is detected.  
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Table 18:  Used Antibodies for Westernblot 
Primary antibodies 
Antigen Name Produced in reactivity manufacturer dilution 
clonality 
HIF-1 alpha  H1alpha67 
 
Mouse  Human, 
Mouse, Rat 
abcam 1:500 
monoclonal 
HIF-1 alpha HIF-1 alpha clone 54 Mouse Human BD 1:500 
monoclonal 
VEGF mAbcam 68334 
ab68334 
Mouse Human, 
mouse, rat 
abcam 1:500 
monoclonal 
ß-Actin ß-Actin (13E5) rabbit Human, 
mouse rat 
Cell signalling 1:1000 
monoclonal 
Secondary antibodies 
Antigen Name Produced in reactivity manufacturer dilution 
clonality 
Mouse-IgG IgG-HRP Sc2005 goat mouse Santa Cruz 1:2000 
polyclonal 
Rabbit-IgG 
 IgG-HRP (sc-2030) 
 
goat rabbit Santa Cruz 1:2000 
polyclonal 
 
2.1.11 PCR 
 
2.1.11.1 RNA Isolation 
For RNA extraction, the phenol-chloroform method is used, a special liquid-liquid extraction 
method for RNA, but also DNA and protein. For this, an aqueous sample is needed which is 
mixed with water saturated phenol and chloroform. By centrifugation, the phases are separat-
ed and split up, containing RNA and DNA in one, protein in another phase. As a last step, 
RNA is precipitated with 2-Propanol or ethanol. 
RNA is isolated from tissue samples with TriReagent after manufacturers protocol.  50-
100 mg of the tissue sample is homogenized after putting them in the adequate volume of 
TriReagent (1ml) and 0.2 ml Chloroform are added. Tubes are shaken vigorously for 15 s and 
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incubated at room temperature for 2-3 min. Samples are then centrifuged at 11000 x g for 15 
minutes at 4°C. After centrifugation, the homogenized samples are splitted into three phases – 
a lower, red phenol-chloroform phase, an interphase and an aqueous upper phase. For RNA-
isolation, only the aqueous phase is carefully removed and transferred into another 
Eppendorf-tube and 0.5 ml of isopropyl alcohol is added. Differing from the original protocol, 
samples are incubated overnight at -20°C to enhance precipitation. The next day, samples are 
centrifuged at 11 000 x g for 10 min at 4 °C. The supernatant is removed and the remaining 
pellet is washed two times with 1 ml 75% ethanol in DEPC-water by mixing the samples by 
vortexing and centrifugation at 7500 x g for 5 min at 4°C. After this, the pellet is air-dried for 
10 mins and shortly dried at 55°C until the opaque pellet turned transparent. At the end of the 
procedure, the RNA is dissolved in 30 µl DEPC-water and incubated on a shaking heater for 5 
minutes at 55 °C. 
 
2.1.11.2 cDNA Ttranscription  
As RNA can’t be used for PCR, it is transcribed into cDNA using the enzyme reverse tran-
scriptase. cDNA is the reverse transcribed product using iScript cDNA synthesis kit according 
to the manufacturers protocol. 1 µg of RNA is mixed with 1 µl transcriptase and 5 µl reaction 
mix, then the volume is filled up to 20 µl with DEPC-water. The samples are shortly 
centrifugated and reverse transcription is executed in a thermocycler and diluted 1:10 with 
PCR-water. 
 
2.1.11.3 Realtime PCR 
The polymerase chain reaction (PCR) is used to amplify DNA so few copies can be replicated 
into great numbers. It works with different phases of heating and cooling cycles. The heating 
process is needed for the DNA melting – to produce single strands where the polymerase can 
bind – and the enzymatic reaction. The polymerase which is used is heat-stable and the best 
known is the Taq-polymerase from the bacterium Thermus aquaticus. The polymerase can 
bind on the single strand DNA in 5’ to 3’ direction and uses nucleotides to build a new anti-
sense strand. The selectivity of the PCR results from the primers, which are a sequence of 
nucleic acid that are complementary to selected regions of the targeted sequence. 
The realtime polymerase chain reaction (realtime-PCR) is based on the PCR, with the addi-
tional feature that amplified DNA can be detected during the process, in ‘realtime’ different 
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from the normal PCR, where the detection is only at the end of the amplification. This is usu-
ally achieved by appropriately designed primer sets that generate a triggered fluorescence 
signal upon the hybridization/polymerization process. Thus, the DNA can be measured and 
either be quantified to an absolute number of copies or a relative amount, compared a so 
called housekeeping gene, in this case ß-Actin. Realtime PCR is performed, using the Step 
One Plus realtime PCR and the Power SYBR Green PCR Mix. mRNA levels are always nor-
malized to ß-Actin. The following oligonucleotides are used: 
rCXCR4 forw. CACCAACAGCCAGAGCGCGA, rev. TGCGCTTCTGGTGGCCCTTG; 
rVEGF forw. CCAGGCTGCACCCACGACAG, rev.:CGCACACCGCCATTAGGGGCA; 
rICAM-1 forw. CGCAGTCCTCGGCTTCTGCC, rev. CGCAGTCCTCGGCTTCTGCC; 
rACTB forw. CTTGCAGCTCCTCCGTCGCC, rev. CTTGCTCTGGGCCTCGTCGC; 
rVCAM-1 forw. GGTGGCTGCACAGGTTGGGG, rev. ACCCACAGGGCTCAGCGTCA; 
rCD 163 forw. TGGGATCGCCGTGACGCTTC, rev. CAGCGACTGCCTCCACCGAC; rIL-
4 forw. GGCTTCCAGGGTGCTTCGCAA, rev. GTGGACTCATTCACGGTGCAGC 
A mixture is prepared which contains the DNA-template, the two complementary primers, the 
nucleotides, the polymerase and special buffers. In this case we use the commercial Power 
SYBR Green PCR Mix and add the designed primers as mentioned above together with our 
sample DNA. The realtime PCR consists of different steps like initialization, denaturation, 
annealing and elongation. The initialization is needed to activate the polymerase. By disrupt-
ing the hydrogen bonds between the base pairs during the heating up in the denaturation step, 
the DNA is melted and the double strand splits into the single strands which is important for 
further steps as the polymerase can only bind on the single strand. In the annealing step, the 
temperature is lowered again to allow the primers to anneal to the single strand DNA mole-
cules. A close match of the primers is of great importance for good binding. Once bound, the 
polymerase can attach to the primer-template hybrid and starts DNA synthesis. The tempera-
ture at the elongation steps depends on the optimum activity temperature of the used polymer-
ase but is commonly 72°C. The polymerase synthesizes a new DNA strand in 5’-3’ direction, 
using the oligonucleotids. The time that is needed depends on the polymerase but also on the 
length of the template. In this steps, the amount of DNA is doubled and leads to exponential 
amplification and huge amounts of DNA, even with only few template molecules of DNA in 
the beginning. 
The optimal temperatures of the realtime PCR were evaluated in the beginning and 40 cycles 
were run. (Table 19) 
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Table 19: Parameters of the real time PCR cycles. 
Status Temperature Time 
Activation of TAQ-
polymerase 
95°C 10 minutes 
Denaturation of cDNA 95°C 15 seconds 
Annealing 60°C 10 seconds 
Elongation  72°C 20 seconds 
Heating up and measurement 
of fluorescence  
84 °C 5  seconds 
Melting curve 65-95° C in steps of 0.3° C  
 
2.1.12 Statistical Analysis  
For stastistical analysis, Graph Pad Prism® 5.02 software is used and results are displayed as 
means +/- standard error of the mean (SEM). Statistical significance is calculated using 
Oneway ANOVA followed by Student’s t-test. Statistical significance is set to p < 0.05. 
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3 Results 
3.1 Establishment of the Orthotopic Lung Transplantation Model 
The animal model of lung transplantation has many benefits for observation of a most similar 
situation to the clinic. But on the other hand, it also bears many difficulties compared to other 
used methods for simulation of lung transplantation, e.g. the trachea graft model. A complete 
thorax-surgery with a transplanted lung graft means big stress for the animal and requires pre-
cise control of animal health and pain management to ensure no unnecessary stress to the rats. 
Besides that, the surgery method itself has to be well established to guarantee comparable 
results and sources of error have to be found and erased by refining of the used method.  
 
3.1.1 Anaesthesia 
Preparation and Premedication: 
All rats (donor and recipient) are pre-anesthetized with a body-adapted dose of Keta-
mine/Xylazine combination with a 75:10 ratio. 100 µl of this mixture are given per 100 g 
body weight intraperitoneally (i.p.). As preoperative pain-management 0.05 mg/kg Buprenor-
phine is given subcutaneous. A well anaesthesia is reached after 4-6 minutes.  
Rats are shaved on a different table to avoid contamination of the surgery table with fur and 
the skin is disinfected with a standard skin-disinfection. 
Donor-rats are shaved generously from the ventral and lateral abdomen to the jawbone and 
recipient-rats are shaved on the left lateral body-wall from the spine down to the sternum.  
 
Intubation and maintenance of anaesthesia: 
The pre-anaesthetized animals are rested on the back and the mouth was kept open with the 
tongue pulled out (Figure 9 a). The opening of the trachea is lightened with the cold light 
source that is set on the trachea. The trachea presents itself as a small spot and is best hit with 
the tubus by sliding it along the ground of the lower jaw (Figure 9 b). To prevent the trachea 
from swelling, a Lidocaine-spray soaked swap is used to carefully spot the area around the 
trachea. For intubation, a common 16G venous catheter is used of which the sharp end is cut 
and blunted. To prove if the tubus is lying in the trachea, the animal is ventilated shortly and 
if positive, the catheter is fixed with a loose surgical knot to the cheeks skin.  
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The rats are ventilated with 85 beats per minute and a maximum pressure of 25mbar, positive 
end-expiratory pressure (PEEP) against atmospheric pressure. Isoflurane is vaporized with 
1.5% as maintenance of narcosis.  
 
 
Figure 9: Schematical drawing of the intubation of a rat. a) Frontal view. The rat is positioned at the 
edge of the table and the upper jaw is fixated with a strong thread. The tongue is pulled out carefully 
and the light source is put in position. Now the opening of the trachea presents itself as a light spot. b) 
Cross section of the head. The tubus, made of a venous catheter, is best positioned by sliding it along 
the tongue. If reaching the trachea, a slight scraping can be felt which is caused by the cartilage rings 
of the trachea. Most animals show a reflective interruption of breathing when the trachea is touched, 
so the rat should be ventilated soon after. T = trachea; O = oesophagus; N = nasopharynx; V = oral 
cavern; C = venous catheter for intubation; L = cold light source. (Illustration by Ockelmann®) 
 
3.1.2 Preparation of the Animals According to our Adapted Method 
Preparation of the Donor Lung: 
The donor-rat is embedded on the back and the skin is disinfected. Then the skin is cut in a 
line from the abdomen to the throat (Figure 10 a)). The skin is dissected, avoiding opening 
the muscles, and then, the abdominal muscles are cut in the Linea alba until reaching the 
Processus xyphoideus of the sternum (Figure 10 b)). Before opening the thorax, the donor is 
treated with 150 IU heparine by injection in the Vena cava inferior (Figure 10 c)). The ster-
num is cut in the median of the Vertebrae sterni to the first rib. The ribcage opened to both 
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sides and it is spread with mosquito clamps on each side. The long lingual muscles were 
primed carefully, and the trachea, which lies in the median of the muscles, becomes visible 
(Figure 11).  
 
 
Figure 10: Schematical drawing of the opening of the rat. a) The skin is cut from the pubic bone to the 
jaw angle and carefully primed to avoid contamination with the unsterile outer side. Now, the abdomi-
nal muscles come to view, which are separated by the Linea alba, the aponeurosis of the abdominal 
muscles. The abdomen should be cut in the Linea alba, the pectoral muscles can be cut from the first 
rip to the Processus xyphoideus. b) View on the opened abdomen with the prominent liver and the 
convolute of the intestine. Once separated from the pectoral muscle, the ribs come clearly into view. c) 
By shoving the intestinal convolute to the right side and lifting the liver carefully with cotton buds, the 
Vena cava caudalis appears and the heparine can be injected directly in the prominent vessel – to 
avoid to much blood loss, the puncture should be compressed with a cotton bud afterwards for a few 
seconds. S = sternum; X = Processus xyphoideus; R = rip; T = thymus; H = heart; L = liver; V = Vena 
cava caudalis; G = stomach; K = kidney; P = preputial gland; a = skin with subcutis and cutaneus 
muscle; b = abdominal muscles; c = Linea alba; d =M..pectoralis; e = abdominal muscles completely 
cut; f = long hyoid muscles. (Illustration by Ockelmann®) 
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Figure 11: Schematical drawing of the opening of the thorax. a) With a strong preparation scissor, the 
sternum is cut in the median, from the Processus xyphoideus up to the first rip. If the ribcage is com-
pletely cut, it opens easily and can be fixated with e.g. mosquito forceps to widen it. If not already cut, 
now, with the lungs visible, the diaphragm is cut and in young animals, also the prominent thymus has 
to be dissected – therefore, only the apex should be cut, as the cutting of the big blood vessels in the 
basic leads to massive bleeding. S = sternum; X = Processus xyphoideus; R = rip; T = thymus; H = 
heart; LL= left lung; RL = right lung; PL = post caval lung lobeV = vena cava caudalis; f = long hyoi-
dal muscles; h = M. omohyoideus; i = Mm. intercostalis; j = M. longus capitis; k = M. deltoideus; l = 
saliva glands; m = diaphragm; t = trachea. (Illustration by Ockelmann®) 
 
Perfusion: 
For perfusion, the heart must be free from remaining tissue like mediastinum or pericardium. 
In young rats, the prominent thymus, which lies still over the heart-base, has to be dissected.  
With a fine straight scissor, the right ventricle is cut in the middle deep enough to open the 
lumen. Soon after that, the left atrium is also incised.  
A venous catheter (16G) which is connected to a tube containing 20 ml of cold perfusion so-
lution (4°C) with Perfadex
®
- or Ringer
®
-solution with a few drops of heparine, is slid through 
the opening in the right ventricle and positioned in the ‘Truncus pulmonalis’ (Figure 12).  
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Figure 12: Schematical drawing of the perfusion method a) Schematical drawing of the cut into the 
ventricle with the already opened left atrium. The venous catheter lies in the pulmonary artery so that a 
direct flush of the lung is guaranteed. b) Scheme of the flow of the perfusion solution. A = Aorta; V = 
Vena cava; PA = Pulmonary artery; PV = Pulmonary; s = Superior lobe of right lung; m = Middle lobe 
of right lung; i = Inferior lobe of right lung vein; RV = Right ventricle; RA = Right atrium; LV = Left 
ventricle; LA = Left atrium; VC = Venous catheter for perfusion. (Illustration by Ockelmann®) 
 
If the perfusion is effective, the lungs soon turn pale and become white. The flushing is 
stopped before air is reaching the circulation. 
After that, the trachea is dissected by carefully cutting the connecting fascia between the long 
lingual muscles and then separated from the oesophagus by carefully pushing a closed scissor 
between them and then opening the blades.  
Now a loose ligature is laid around the trachea and pulled tight in the phase of deepest inspi-
ration, so that the lungs are filled with air. The trachea is then separated cranial to the ligature 
and the whole heart-lung package is removed, avoiding especially damage to the left lung. 
A bended fine preparation scissor is used, with the bended side always in direction to the 
lung. The scissor should cut in a vertical direction with only little opened scissor blades and 
the tip always at the spine.  
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Storage of the Heart-Lung Package: 
Directly after removing the heart-lung package, it is carefully wrapped into a moist gauze in a 
Petri - dish. Then the lung can be stored on ice or in a fridge at 4°C for the subsequent proce-
dures.  
 
Cuff-Sleeve-Technique: 
Cuffs are made out of 17G or 16G venous catheter parts which are cut into pieces of 3-4 mm 
length. Each of the pieces is then cut vertically in the centre with a scalpel. The cut is about 
the half of the diameter. A second cut is made horizontal from the end to the first cut and the 
fragment removed, so that a strap remains. Any sharp edges were blunted to avoid damage to 
the tissue (Figure 13).  
 
Figure 13: Schematical drawing illustrating the preparation of the cuff. a) The 3-4 mm piece of the 
venous catheter is first incised to the median in both directions (I.). The flap is cut as short as possible 
so it can still be hold with a microneedleholder but at least to the half. The remaining side walls are 
carefully cut, avoiding any sharp edges (II.). b) Sketches of the three possibilities of cuffs used for 
lung transplantation. Mizutas original cuff (I.), Zhais cuff without any flap (II.) Our cuff with a short 
flap (III.) (Illustration by Ockelmann®) 
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For the fixation to the cuff, ligature-loops (double surgical knot) of 6-0 Prolene thread are 
used. During preparation, the lung is still kept in the Petri - dish and kept cool and moist. The 
next working steps are accomplished under the microscope. For microsurgery two micronee-
dleholders, one microscissor and one lockable microneedleholder are needed. 
 First the heart-lung package is positioned in the same way as in situ with the heart on top. 
The artery, vein, and bronchus are wrapped in connective and fat tissue that has to be re-
moved very thoroughly. All structures are cut as long as possible. First, the vein is dissected. 
It is the structure most caudal and usually very short in the Sprague Dawley rats. Therefore it 
is first dissected from remaining tissue and then cut in the confluence of the left atrium. Next 
the artery is primed and at last, the bronchus (Figure 14).  
 
Figure 14: Schematical drawing of the preparation of the three important structures, surrounding tis-
sue is already removed a) First the vein is cut in the confluence of the left atrium by cutting before the 
branch of the post caval lobe departs b) The artery is also cut as heart-near, as possible. c) The bron-
chus can only be primed safely after the vein is already shoved aside. It is cut in the Pars membrana-
cea in the Bifurcatio trachea; LA = left atrium; LV = left ventricle; PA = pulmonary artery; PV = 
pulmonary vein; AB = accessory branch of the pulmonary vein; B = bronchus; LL = left lung. (Illus-
tration by Ockelmann®) 
 
For the vein, a 16G cuff is clamped with its strap in a lockable microneedleholder with the 
round open end showing upwards. The free end of the vein is carefully grabbed with the mi-
croneedleholder and pulled through the cuff. Once the end is slipped completely through, the 
vein is turned upside-down over the cuff and fixed with a 6-0 Prolene ligature. The strap is 
left free, so it can be hold. It has to be checked whether the lumen of the vein is completely 
continuous and the vessel is not twisted during the procedure.  
The same procedure is performed for artery and bronchus, using a 17G cuff for the artery and 
a 16G cuff for the bronchus (Figure 15).  
Results 
 
59 
After this, the heart and the right lung are dissected and discarded. The prepared left lung is 
then again stored as described before until the recipient is prepared for transplantation.  
 
Figure 15: Schematical drawing of the cuff-technique a) The cuff is clamped. b) The structure is care-
fully shoved through and dragged with a microneedleholder c) Once completely shoved through, the 
walls are carefully grabbed with the microneedleholders. d) The structure is everted over the cuff. e) 
The so prepared vessel is hold in position by the surgeon while the assistant is fixating it with the pre-
pared thread-loops. f) After ligation, overlapping tissue is cut with a microscissor. g) The cuff, ready 
for transplantation. (Illustration by Ockelmann®) 
 
3.1.3 Recipient Preparation 
Ligature-loops are made of 5-0 silk threat (double surgical knot). Meanwhile 2-3 sterile com-
presses are soaked in sterile NaCl-solution and precooled.  
A syringe with a 1:100 diluted Heparin/NaCl-solution is prepared (Heparin 25,000 I.U.) and 
assembled with a blunted cannula. A syringe with atropine and another one with a 1:100 solu-
tion of adrenaline are also prepared.  
Anesthesia, intubation, ventilation and shaving are performed as described earlier.  
The rat is embedded on the right body side and the light source of the microscope is adjusted 
to the thorax. Before starting the surgery, a dose of 50 µl atropine is injected intramuscularly 
in the quadriceps against bradycardia.  
The cutting line is between the 4.-5. intercostal space, which can be found by an imaginary 
line drawn from the straight spine to the shoulder and elbow in normal flexion (Figure 16).  
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The intercostal space can then be palpated. We found out, that the 5th intercostal space is the 
best choice in young animals, as the prominent thymus still covers the organs in the 4
th
 inter-
costal space.  
 
Figure 16: Schematical illustration of the cut. a) Transversal section of the thorax of a rat lying on the 
right body side b) First cut through the skin. (Illustration by Ockelmann®) 
 
3.1.4 Transplantation Procedure 
To establish the method of the orthotope left lung transplantation, we first used a method, that 
was described earlier by Zhai et al
226
 and leads back to the method of Mizuta et al
227
 who 
invented the cuff-technique for the lung transplantation. The method of Zhai, which was used 
for our first group, is not described here and only the modified method by our group is de-
scribed below.  
Surgery: 
With a surgical scissor, the skin is cut straightly and the muscles are primed. The cut is started 
dorsal and elongated in ventral direction. Big blood vessels are cautered with a thermocauter 
or clamped with a mosquito forceps. After cutting the M. latissimus dorsi and M. serratus 
ventralis, the ribs and the M. intercostalisare visible. First a small incision is made in the de-
terminded intercostal space with a straight small scissor, so that the thoracic cave is opened. 
To avoid cutting any big vessels, the cut should be made on the cranial part of the caudal rip 
belonging to the chosen intercostal space and it should be avoided to elongate the cut ventral 
as the mammary artery is located there. The final cut is about 1-1.5cm long (Figure 17). 
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Figure 17: Schematical drawing of the thorax opening (transplantation). a) Subcutis and muscles are 
primed and bigger vessels clamped or thermocautered. The 5th rip comes into view b) By cutting 
along the cranial side of the 5th rip, cutting in the vessels and nerves is prevented as they are better 
protected on the cranial side than on the caudal side. In the right position, the left lung comes into 
view, together with caudal parts of the thymus c) The rips are spread with a rip-spreader. (Illustration 
by Ockelmann®) 
 
Once opened, the heart and the left lung are visible. To spread the cut, a rip spreader is 
hooked in and the opening is widened carefully. The left lung is moved out of the body with 
two swabs, trying first to move the cranial part an then the longer caudal part (Figure 18).  
 
Figure 18: Schematical drawing of the retrieval of the left lung a) by gently rolling along the cranial 
parts of the lung with a sterile swab. The tip of the lung can be moved towards the wound opening and 
then fixed with another swab from the backside. b) Once completely put out of the wound opening, the 
lung is clamped with a special lung clamp and fixated. (Illustration by Ockelmann®) 
 
All next steps are done under the microscope.  
The vessels and the bronchus are carefully dissected from the surrounding fat and connective 
tissue and primed. Blood and other liquids are removed frequently using swabs (Figure 19).  
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Figure 19: Schematical drawing of the fixated lung. a) If fixed in the right position the lung base 
comes into view, still covered in connective and fat tissue. b) After removal of surrounding tissue and 
preparation of the three structures, ligation threads are carefully layed around every structure. Touch-
ing of the heart and the Nervus phrenicus are avoided. LL = left lung; H = Heart; T = thymus; n = 
Nervus phrenicus. (Illustration by Ockelmann®) 
 
All three structures are ligated with a 6-0 Prolene loop and fixed under light tension. A 2 mm 
cut is made with the microscissor in the front wall of artery and vein. For the vein, it is best, 
to cut in the arborisation on the dorsal end of the vein near the hilus. The bronchus should be 
cut later to avoid aspiration of liquid. Artery and vein are rinsed with the prepared 1:100 di-
luted Heparin-solution until they appear bloodless. Therefore, the cannula of the syringe must 
to be blunted. After clearing and swabbing the liquid out of the thorax, the bronchus is cut 
(Figure 20).  
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Figure 20: Schematical drawing of preparation of the recipient’s vessels and bronchus. a) All three 
structures are reversible ligated with a single loop of a thread. The threads are fixated outside of the 
wound opening. b) The vessels are incised on the front wall and flushed with a solution of heparine 
(1:100) until they appear free of any left blood. The bronchus is incised after removal of every fluid. 
Loops of silk threads are laid around prepared structures. LL = left lung; A = artery; B = bronchus; V 
=vein; H = heart. (Illustration by Ockelmann®) 
 
Finally a 5-0 silk thread is laid around the structures in a loose double-surgical knot. The do-
nor lung is now fetched out of the can storage, wrapped into a cool, moist gauze and placed 
on top of the recipient’s lung. The strap is fixed with a microneedleholder and the cuff is care-
fully slid into the opening of the recipient’s vessels and bronchus as deep as reached. Again it 
has to be checked, whether the structures were not twisted. Once in the right position, the silk-
knot is tightened around the cuff. In an optimal case, the silk ligature lies on the Prolene-
ligature.  
After all ligatures are tight enough, the vessel loops around the vessels and bronchus are re-
moved, so that reperfusion and reoxygenation is started. 
First the thread around the vein is cut, and watched if retrograde reperfusion occurs, ensuring 
the venous drainage, then the artery follows. If the lung appears to be filled with blood again, 
at last, the loop around the bronchus is removed.  
Now the remaining recipients left lung lobe is carefully dissected via cutting the remaining 
connection to the tissue on the vessels and bronchus via microscissor (Figure 21).  
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Figure 21: Schematical drawing of cuff-fixation. a) The silk loops are held in position by the assistant 
while the surgeon puts the cuff into the incised opening of the recipient’s structure as deep as possible. 
b) The silk thread is pulled tight so the cuff can’t slip. The silk ligature lies best directly on the 
Prolene-ligature of the cuff. dL = donor left lung; dA = donor pulmonary artery; dB = donor bronchus; 
dV = donor pulmonary vein; rA = recipients pulmonary artery; rB = recipients bronchus; rV = recipi-
ents pulmonary vein. (Illustration by Ockelmann®) 
 
The transplanted lobe is now moved back into the thorax. For this, the ventilation has to be 
disconnected, so the lung collapses and can be shoved back through the opening. As soon as it  
is in position, ventilation is connected and the lung is shortly bloated, so the atelectatic areas 
are filled with air. After relocating the transplant, 3-4 pieces of threads are laid, so that both 
wound-ends can be connected adequately. A venous catheter is placed in the ventral corner 
between the two last threads, and the wound is closed with a double surgical knot. Then the 
remaining air and liquid is evacuated via the venous catheter removing it under constant mo-
tion. Then, muscles and skin are adapted to an anatomically correct position and constellation. 
 
3.1.5 Pain Management  
To reduce postsurgical pain, 600µl Ropivacain solution 0.2% is instilled around the wound 
instead of a presurgical pain-management with a aequivalent opoid. This instillation of a local 
anaesthesia serves as a intercostal nerval blockade and was used to avoid the systemical effect 
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of the opioid in the first hours after transplantation especially with the view on the respiratory 
depression. A body-adapted dose of enrofloxacin is given subcutaneously.  
For further postoperative pain-management we used piritramid is used as a strong painkiller 
and administered via drinking water, containing glucose. Therefore, 3 ml piritramid (1.5 
mg/ml) are dissolved in 230 ml water and 20 ml glucose 20% solution is added. The glucose 
is added to reduce the bitter taste of the piritramid.  
The water bottles are weighed in the beginning and then everyday to guarantee an adequate 
supply with piritramid. The rats are observed twice a day and weighed every day.  
 
3.1.6 Effects of Local Anaesthesia after Surgery on Animal Health 
To confirm whether a local anaesthetic intercostal nerve blockade is an adequate analgesia, 
we analysed the animal health, including general condition, physiological status, explorative 
behaviour, motility, full loading of extremities and food and water intake on a scale from 0 to 
10 in which 0 is worst and 10 best (Table 20). 
Awaking animals that got a local anesthesia block show much better motility and full loading 
of the left body side compared to animals only treated with a presurgical single injection of 
buprenorphine. Animals that are treated with the ropivacain-block show an improved general 
condition and even active exploratory behaviour almost right after complete awakening 
(Figure 22). 
 
 
 
 
Figure 22: Comparison of the Animal health between the groups treated with local anesthesia block 
and those who were only treated with ‘classical’ injected opioid presurgical. n=6, **p<0.01. 
Results 
 
66 
Table 20: Parameters of the animal health score. 
Category 
Points 
1 0.5 0 
Recovering 
from 
anaesthesia 
Awakening < 30 min Awakening > 30 min No awakening  
 Soon attempts to move No or only inadequate 
movement 
Exploration 
behaviour 
No discrepancy to natural 
condition 
Hesitant, interest in 
strong stimuli (food, wa-
ter, other rat) 
No attempts  
Loading of 
extremities 
No discrepancy to natural 
condition 
Relief of anterior body 
part, but movement of all 
extremities  
Hesitant setting of extremities, 
only moving if necessary, much 
resting 
Breathing No discrepancy to natural 
condition 
Careful breathing and 
movement of thorax, 
slight respiratory sound 
Gasping for air with open 
mouth, strong respiratory sound 
Pilierection  No discrepancy to natural 
condition 
Slightly, over the first day Strong, lasting over the second 
day 
Social groom-
ing  
No discrepancy to natural 
condition 
Restricted social groom-
ing  
No social grooming  
Food and water 
intake 
No discrepancy to natural 
condition, gaining weight 
Acceptable intake, loss of 
bodyweight < 10% 
Inacceptable or no intake, loss of 
bodyweight > 10% 
Pain signals  No discrepancy to natural 
condition 
Slight signs of unwell 
feeling over the first hours 
after surgery  
Signs of pain, apathy 
Individual 
body care 
No discrepancy to natural 
condition 
Restricted body care 
(Hadersches secret around 
the eyes, scruffy fur) 
No body care 
Interest in the 
enviroment 
No discrepancy to natural 
condition 
Interest only to strong 
stimuli  
No interest 
 
more than 2 fields that are high-
lighted in grey  
1 field highlighted in grey and bold 
letters  
 
more than 2 fields in italic let-
ters  
termination of experiment and hu-
manely killing of the rat 
termination of experiment and hu-
manely killing of the rat 
prove of pain management 
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3.1.7 Surgical Complications  
To compare the method of Zhai et al 
226
 with our modified transplantation procedure, three 
categories of cause of death are taken into consideration (Figure 23, Figure 24): 
The first category includes animals that are included in the end of the experiment, have sur-
vived the transplantation and the 48 h postsurgical observation time. Another category de-
scribes animals that have died due to surgical complications which correlate to problems that 
are linked to the surgical procedure itself as damage to important structures by instruments or 
unstoppable bleedings due to loosening of clamps or ligatures. Finally, a last category com-
prises animals that have died due to other causes including unpredictable problems that lead 
to exclusion from the experiment like heart arrest or pathological conditions that were unas-
signed to the experiment. 
Taken together these data indicate that, compared to the method of Zhai et al
226
, the modified 
method is less sensible to surgical complications that ended in exclusion of the animals. 
 
Figure 23: Cause of death according to the surgery method. n=11  
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3.1.8 Time Cost of Surgery  
Moreover, the modification of the surgical procedure is a benefit for the time needed to com-
pletely transplant the lung. The graph shows the time difference for the surgical procedures, 
which is defined as the time from the start of the warm ischemia of the lung when the lung is 
taken from the cold storage until the moment of the complete adaption of the transplant and 
prove of the function. Our method is significantly faster than the one described by Zhai et al 
226
(Figure 25).  
 
Figure 24: Cause of death in a group score that shows a significant difference in surgical complica-
tions regarding the two methods. n=11, *p< 0.05. 
Figure 25: Comparison of the time needed for surgical procedure with the modified and Zhais 
method. n=11, **p<0.01. 
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3.1.9 Comparison of the Survival Rate  
Comparing the survival rates of all animals in the both groups, we have found that our modi-
fied method results in a much better outcome. The graph shows the days of survival in %, 
with the complete time period of 48h as 100%. In the group that is treated according to the 
method of Zhai
226
, a mean survival of 40% is reached, whereas our modified method group 
reached a mean survival of 80% (Figure 26).  
 
 
Figure 26: Survival rate comparing both surgical methods. n=11 
 
3.2 Pilot Experiment 
3.2.1 Cell culture Experiments 
3.2.1.1 Dose dependent Effects of Deguelin on HIF-1 α in vitro  
To prove the anti HIF-1 effects of Deguelin, we first determined its inhibitory capability in a 
cell culture experiments. As described previously, Deguelin was tested at increased concentra-
tions under hypoxia as well in HMECs as in HTB-177.  
With a working concentration of 100 nM we showed that after 6 h of hypoxia Deguelin effec-
tively reduces HIF-1α protein expression in HMECs and HTB-177 compared to normoxia-
controls. DMSO (solvent) alone has no suppressive effect and hypoxia alone stabilizes HIF-
1α as expected. (Figure 27 a)  
Deguelin also inhibits exemplary downstream-genes of HIF-1α in a concentration dependent 
manner. The mRNA of CAIX, VEGF, LOX, ANGPTL4, EGLN3 and ADM are significantly 
downregulated compared to untreated hypoxic cells. To verify that Deguelin is not a general 
transcription inhibitor, EGLN2 is used as negative control (Figure 27 b).  
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Figure 27: Effects of Deguelin in vitro. a) Western analysis of HTB-177 and HMEC cells following 
treatment with Deguelin under normoxia and hypoxia (6h). b) mRNA levels of HIF-1α target genes 
under influence of normoxia, hypoxia and Deguelin treatment in combination with hypoxia. HIF-1α 
protein is decreased at a Deguelin concentration of 100nM and 6h hypoxia. Deguelin also suppresses 
down-stream genes concentration dependent. n=3, *p< 0.05, **p<0.01 ***p<0.001. 
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3.2.2 Animal Experiments 
3.2.2.1 Toleration of Deguelin Gavage 
To reach adequate tissue levels of Deguelin in the animals, we chose to feed via intragastrical 
gavage. This method can be executed without anesthesia. Animals are treated with Deguelin 
dissolved in DMSO at 4 mg/kg bodyweight with an end volume of 200 µl. The rats receive 
the Deguelin intragastrically via gavage twice a day at a volume of 100 µl. All animals in the 
experiment tolerated the gavage very well and all of them gain weight (297.8 ±9.805 g and 
335.6 ±2.064 g vs. 257.1 ±4.389 g, P=0.0009, P<0.0001 resp.) compared to a group only 
treated with solvent. Nevertheless, animals treated only with solvent were significantly heav-
ier than those treated with Deguelin (335.6 ±2.064 vs. 297.8±9.805, †P=0.0196), but no harm-
ful effects of the treatment are observed in both groups (Figure 28)  
 
 
Figure 28: Bodyweight after treatment with Deguelin. n=6, ***p<0.001, †p<0.05. 
 
3.2.2.2 In vivo Effects of Deguelin on HIF-1α  
To examine the in vivo effects of Deguelin, lungs of rats treated with the inhibitor, were ex-
posed to warm ischemia (37°) for 1 h. For controls, lungs of non-treated rats are harvested and 
immediately snap-frozen in liquid nitrogen.  
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Realtime-PCR measurements reveal that there are detectable basal mRNA levels under basal 
control (SHAM) for VEGF (100.0±12.28), CXCR4 (100.0±19.97) and ICAM-1 (99.9±12.28). 
Under warm ischemia, upregulations of VEGF (217.8±44.98; P=0.0338) and CXCR4 
(272.0±60.82; P=0.0291) are significant compared to the SHAM-group, whereas the changes 
in ICAM-1 (136.5±18.93; n.s.) show no significant regulation. A inhibition of HIF-1 by 
Deguelin showed significant downregulation compared to the warm ischemia group foVEGF 
(217.8±44.98; P=0.0338), CXCR4 (272.0±60.82; P=0.0291) and ICAM-1 (42.4±7.36; 
P<0.0001). The gene expression of the corresponding negative control β-Actin (ACTB) re-
mained unchanged.  
 
 
Figure 29: mRNA level of various HIF-1 target genes in sham lungs and lungs that were exposed to 
warm ischemia with or without treatment with Deguelin. n=6, *p< 0.05, ***p<0.001, †p<0.05, 
††p<0.01, †††p<0.001 
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3.2.2.3 Effects of HIF-1 Blockade on the Lung Microstructure  
Besides the molecular changes, we also examined the microstructure of the lung tissue. As the 
destruction of the alveolar integrity by flooding with extravascular liquid and the resulting 
lung edema is one of the most critical points in the maintenance of lung function, this change 
of lung structure has to be investigated carefully (Figure 30). Therefore, micrographs of the 
lung samples are taken at 10x and 40x magnification. 3 randomly taken pictures are made 
from every slice and the tissue area (blue) is compared to free space area (white) (Figure 31). 
Tissue edema and damage seen directly correlates with the increase in area compared to free 
space. This data demonstrates that the rates differ significantly between the compared groups. 
Lungs from the Deguelin group have significant lower edematous changes shown in massive 
thickening of the thin cell-layer and loss of free air-filled space between the alveoli 
(36.5±2.88 % tissue / area) than animals from the warm ischemia group (55.2±2.73 % tissue / 
area). This values are even higher than the ones for the SHAM animals (50.5±1.34 % tissue / 
area). In the lungs of the animals, that have received the Deguelin therapy, the microstructure 
of the lung is preserved best whereas the lung structure from lungs of the warm ischemia 
group show massive thickening of the tissue (Figure 32).Interestingly, the lungs from the 
SHAM animal group show almost the same tissue changes like the lungs exposed to warm 
ischemia. 
 
 
Figure 30: Tissue of a lung graft exposed to ischemia (37°C) for 1h. The thin tissue structure of the 
alveoli has thickened rapidly (left picture). For comparison, the normal tissue of the lung with the thin 
endothelial layer of the alveoli (right picture). 
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Figure 31: Comparison of tissue area vs. non tissue area of Deguelin treated lungs and those without 
treatment exposed to warm ischemia. n=6, ***p<0.001. 
 
 
Figure 32: Micrographs of tissue slides from lungs of sham-group, warm-ischemia without treatment 
and Deguelin treated animals. The 10x magnification (first row) is evaluated via measuring the tis-
sue/non tissue area (second row). The swelling of the tissue is presented more closely in the 40X mag-
nification (last row). Deguelin also shows a protective effect from microstructural edema in the 
ischemic lung. w.i. = warm ischemia, w.i.D = warm ischemia + Deguelin. 
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3.3 Effects of HIF-1 Inhibition on LTX Outcome 
 
3.3.1 Effects on VEGF Protein Expression  
To prove that Deguelin is effective in suppressing a reperfusion edema, a wet-to-dry ratio for 
the lungs of the transplanted animals are determined to evaluate edema formation. Animals 
from the Deguelin-treated group have significant less tissue edema than animals without 
treatment (Figure 33 a). Corresponding micrographs show that lungs with high degrees of 
edema posess similar structural changes than lungs from warm ischemia group of the prelimi-
nary experiment (Figure 33 b). To determine the role of VEGF in edema formation further, 
western-blot and realtime-PCR analysis are made and show significantly lower levels of 
VEGF protein and mRNA in Deguelin treated animals. These data suggest, that HIF-1α di-
rectly induces tissue edema via VEGF upregulation.  
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Figure 33: Deguelin effectively suppresses VEGF in lung tissue. a) Results of the wet-to-dry ratio 
between control and Deguelin treated animals showing a significant difference between both. b) 
mRNA and protein levels of VEGF after transplantation, comparing animals of the untreated control 
group with the Deguelin group (left). VEGF protein analysis shows also significant downregulation 
(right) in the Deguelin group. Upper band = VEGF, lower band = ß-Actin. n=6, ***p<0.001. 
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3.3.2  Effects of HIF-1 Blockade on Short Term Survival 
Besides the decrease of the tissue edema, the Deguelin treated animals have a significantly 
improved short-term survival rate compared to the non-treated group. 100 % of the animals 
from the Deguelin-treated group have reached the endpoint of 48 h post transplantation. A 
significant difference is also seen in the mere view of the harvested lungs after 48h (Figure 
34). In the non-treated group there is a mean survival of only 17.42 ± 9.67 hours. The plente-
ous findings directly correlate with the better outcome of survival and seem to be correlated 
with the reduced VEGF expression (Figure 35).  
 
Figure 34: Harvested heart-lung packages from transplanted animals after 48 h. a) Control, b) De-
guelin treatment. L = left lung, R = right lung. 
 
 
 
 
Figure 35: Mean survival of the transplanted animals, comparing the control group to the HIF-1 inhi-
bition group in hours (h). n=6, *p< 0.05. 
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3.3.3  Effects of Deguelin on the Immune Response 
As described in 1.3 the immune system plays an important role in the reaction to the graft, 
because it can induce negative reactions  like the destruction of tissue and the initialization of 
subsequent processes like PGD or rejection (Figure 36, Figure 37). The investigation of the 
histological slides, shows that a huge amount of macrophages can be observed in the 
Deguelin treated group, that are only found in the lungs of surviving animals with a good clin-
ical appearance. Due to the normal inflammatory role of lung-macrophages this seems to 
stand in contradiction to the significantly improved survival rate and health of the animals 
from the Deguelin group. This may be an indicator that these macrophages might play a role 
in the healing process of the lung tissue. This hypothesis is supported by the detection of 
markers for anti-inflammatory macrophages as CD 68 + and CD 163 via immunostaining. 
These markers show a much higher abundance of macrophages like M2-macrophages in the 
Deguelin-treated animals. These cells are known to exhibit an anti-inflammatory role. CD 
163+ (1262.0 ± 266.6 vs. 100.0 ± 18.5; P=0.0008) and CD 68+ (8.500 ± 2.225 vs. 37.81 ± 
5.499 ; P= < 0.0001) are significantly upregulated in HIF-1 blocked lungs. It is known that 
usually there are only macrophages of the CD 68+ type stay in the lung. Thus, these findings 
give rise to the assumption that the macrophages of the CD 163 type are from a systemic 
source (Figure 38). 
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Figure 36: H&E staining of a transplanted left lung of an animal that died early on severe PGD. The 
blood filled vessel shows a massive appearance of white blood cells (arrows), that show typical ‘roll-
ing’ and migration on the intima of the vessel. 
 
 
Figure 37: Massive infiltration of lung tissue via leukocytes in a transplanted lung. 
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Figure 38: Histological pictures of slides of transplanted lungs. a) Histological stains of control and 
Deguelin treated animals in H&E stains, no macrophages are found in the control, but in the Deguelin 
group (arrows). b) statistical analysis of the findings in the staining of CD 68+ and CD 163+ cells 
comparing control and Deguelin group. Significantly higher levels of cells can be found in Deguelin 
treated animals. n=6, ***p<0.001. 
 
Besides the recruitment of M2 macrophages, the HIF-1 inhibition also leads to the 
downregulation of pro-inflammatory proteins as ICAM-1 and CXCR4. There is also an 
upregulation of IL-4 (153.1 ± 14.5 vs. 100.0 ± 17.2; P=0.0357) which is known to have 
immunomodulatory influence. This is interesting especially considering findings that the lev-
els of CD 163 are also increased, which are indeed, amongst others, induced by IL-4.
74, 75
 Fur-
thermore, ICAM-1 (26.5 ± 5.3 vs. 127.8 ± 49.6; P=0.0188) and CXCR4 (58.9 ± 8.7 vs. 107.7 
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± 20.6; P=0.0274) gene expression was significantly downregulated in HIF-1 blocked animals 
compared to controls (Figure 39, Figure 40).  
 
 
 
 
Figure 39: Results of mRNA analysis of relevant HIF-1 gene products. The control and the Deguelin 
treated group are compared. It shows an upregulation of CD163 and IL-4 in the Deguelin group, 
whereas CXCR4 and ICAM-1 are downregulated, showing that HIF-1 blockade leads to a systemic 
anti-inflammatory and immunomodulatory phenotype. n=6, *p< 0.05. 
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Figure 40: Immunostaining for proinflammatory markers a) Immunehistochemical pictures of the 
control and Deguelin group, showing the proinflammatory markers ICAM-1 and CXCR4. b) Statisti-
cal analysis of ICAM-1 and CXCR4 in both groups showing significant downregulation in the De-
guelin group. n=6, p<0.01 ***. 
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4 Discussion 
 
Although a lot of studies have been published that investigate the function of HIF-1 during 
cancer development, its role during hypoxic conditions in tissue of grafts and its effect on the 
immunological reaction have been subject of latest studies.
69, 187, 194, 198
 The role of HIF-1 
seems to be strongly tissue dependent and leads to somehow contradictory results from bene-
fits in HIF-1 upregulation to great disadvantages caused by HIF-1 translated gene products.
168, 
248
 
Effects in the lung tissue such as accumulation of HIF-1 leads to tissue damage due to upregu-
lation of genes as VEGF, or inflammatory genes such as ICAM-1 or CXCR4.
69, 187, 194, 198
 The 
proinflammatory response is a major problem in primary graft dysfunction. Therefore, the 
inhibition of factors that are responsible for the initiation of these pathologic states seems to 
be an effective therapeutic concept. As shown earlier, chronic hypoxia itself may obviously 
lead to inflammatory tissue damage and finally to apoptosis.
173
 However, during transplanta-
tion, ischemia of the tissue and the resulting hypoxic condition are inevitable situations. 
Therefore, inhibition of HIF-1, the major hypoxic factor, is beneficial as it shows not only 
great responsibility in regulation during hypoxia, but also presents itself as capable of strongly 
initiating on inflammatory reaction in the lung tissue.
69
  
Deguelin as a candidate for HIF-1 inhibition was already presented in many studies, although 
it has also been reported to target also other pathways leading all to a downregulation of HIF-
1 protein expression. However the complete mechanism and the concrete way of binding of 
Deguelin still remains unclear. Nevertheless, recent studies mark its function in inhibiting the 
complex I in the mitochondria which suggests that Deguelin acts on a very early point at the 
respiratory chain.
214
 Furthermore, it was also demonstrated that Deguelin can inhibit HIF-1 
without affecting the ROS and Akt-pathway.
209, 222
  
Most of the studies described the effects of Deguelin in cancer cell lines or cancer animal 
models. The reaction of healthy, not altered tissue to Deguelin was tested only in a few mod-
els.
209, 221
 The same is true for its toxicity to the organism.
221
 It was never used as a protecting 
agent for healthy tissue during LTX.  
To ensure that Deguelin has an inhibitory effect in the used concentration, two cell lines of 
immortalized human microvascular endothelial cells (HMEC) and an immortalized human 
epithelial lung cell line (HTB-177) are used in the presented work. These two cell-types are 
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very important for functionality of the lung tissue. In this trial we show a concentration de-
pendent inhibitory effect at 100nM Deguelin in the two cell lines, without visible cytotoxic 
effects. No individual effect is observed for the solvent DMSO.  
As the i.g. application of Deguelin shows better basic levels of Deguelin in the lung compared 
with i.v. and s.c. application, we decided to feed the rats with a dose of 4 mg/kg BW twice a 
day over three days to reach adequate levels in the lung. 
217
 This treatment shows no harmful 
effect to the animals and all gained weight. Also the i.g. gavage is well tolerated using a hand 
trained rat strain, which allows for omittance of the anesthesia.  
In comparison to the SHAM group, a control group of warm ischemia (1h at 37°C) and ani-
mals treated with Deguelin are investigated. The lungs from the control group show macro-
scopical signs of lung edema: like a clear change of their color to dark red and a liver-like 
consistence. Furthermore, the microstructure changes significantly by massive thickening of 
the tissue and a great to almost complete loss of air volume compared to the Deguelin group. 
The lungs from the Deguelin group have a much less dramatic appearance in the first view, 
but they also show significantly less thickening in the tissue. Additionally, the thin alveolar 
structure is preserved much better even in comparison to the SHAM group.  
Deguelin shows a concentration dependent reduction of HIF-1α protein expression, which is 
in accordance with previous studies.
209, 216
 Moreover Deguelin also reduces mRNA levels of 
HIF-1α and HIF-1 dependent downstream-genes as VEGF, CAIX, LOX, ANGPTL4, EGLN3 
and ADM.  
Especially VEGF is of great interest, as it is already known that it acts as major inducer of 
lung edema development. It is shown in earlier studies, that VEGF not only leads to an in-
crease of vascular permeability in an I/R model in rats, but also causes massive pulmonary 
edema. An inhibition of VEGF cell signalling on the other hand can reduce this damage to the 
endothelium.
249, 250
 Its inhibition can lead to prevention of ischemia and reperfusion injury. 
This findings lead to the primary idea of an inhibition of VEGF before its activation. Deguelin 
seems to be perfect pharmacological agent for this purpose, as it has already been demon-
strated to have an influence on HIF-1 and VEGF expression.
216
 Contrary to this idea of an 
inhibition of VEGF, some researchers uphold the opinion that HIF-1 and VEGF upregulation 
results in a benefit for the tissue in graft processes, due to its angiogenetic activity.
251
  Al-
though this hypothesize can be supported by model experiments, using subcutaneous trachea 
transplants, our data suggest that in the case of a fully functional lung transplant, this ap-
proach of VEGF upregulation will not lead to the desired improvements. Several reasons can 
be pointed out for this assumption: First, the angiogenetic activity of VEGF can never be a 
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fast acting effect, which prevents the desired effects from manifesting itself during the early 
phase of reperfusion. Additionally the mere generation of new vessels is not in every situation 
a benefit for the tissue, especially in tissue, that will be disturbed in its function as e.g. the 
retina.
209
 Angiogenesis does not seem to be the most important process in the early phase of 
reperfusion of the lung graft. In this phase, HIF-1 is more likely to be a potent mediator of 
lung edema due to its ability to increase vascular permeability via VEGF during the first 
hours.
252
 Of course, vessel migration can be positive for adaption to blood circulation when 
there is no primary adaption, but a transplanted lung – different than a skin flap or trachea 
graft under the skin – does not need new vessels, as it is adapted directly to the big blood ves-
sels of the recipient. Furthermore, a disturbance of the thin layer of the lung tissue, which is 
responsible for gas-exchange, leads to critical function loss. 
Our data clearly shows the correlation of VEGF mRNA and protein to the development of 
edema in the lung. We also demonstrate the downregulation of both observevables in the De-
guelin group compared to the control in the pilot experiment and after LTX.
249, 250
 As lung 
edema is a very critical situation for the sensible lung structure and complicates or even com-
pletely inhibits the gas exchange, a prevention of edema is essential for the functionality of 
the graft.
252
 
Moreover realtime PCR results show a downregulation of, CXCR4 and ICAM-1while both 
are known to mediate inflammatory processes due to stimulation of leukocyte migration 
through chemotaxis.
17, 253
  
To underline the preliminary data and to prove, whether these findings are translationable to 
the setting of LTX, we apply a HIF-1 inhibitor during orthotope lung transplantation in the 
rat. As a more intense reaction and changing of the tissue is expected after 48h compared to 
the 1h in the pilot experiment, a direct comparison of the thickening of the tissue is not trivial 
to determine histology. Besides the longer duration of the experiment, the edema in the lung 
graft is also a result of the additionally necessary reperfusion. To examine the edema, we 
therefore use a common technique.
181
 The Wet-to Dry ratio as an estimation of tissue water, is 
a commonly used method to determine edematous conditions and shows a difference in the 
water content of the lungs between the untreated group and the group that was treated with 
Deguelin. This leads to the conclusion, that the reperfusion edema has a much stronger impact 
on the untreated group compared to Deguelin treated animals.  
Upon harvest, the left lung of the control group presents itself as almost of liver-like consis-
tence whereas the Deguelin graft is of slight rose color and shows much more lung-like ap-
pearance (Figure 34). 
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The benefit of the HIF-1 inhibition also manifests in the survival of the animals. Whereas 
100% of the Deguelin treated animals reach the endpoint of the experiment at 48h, the control 
group has only a mean survival time of 17.42 ± 9.67 hours and many of them died already on 
acute lung edema in the first hours after transplantation. This emphasizes the role of the im-
munogenic reaction of the recipient’s body to the foreign graft in the control group, which 
negates the theory, that the animals do not have a strong immune reaction at all. In what way 
there is an influence of the close blood relationship in most bred strains on the fact that some 
of the untreated animals reached the 48h is not clear. Although, the used Sprague Dawley 
strain is an outbred strain that should show a wide spectrum of individual antigenes. 
Realtime- PCR analysis of the proinflammatory cytokines ICAM-1 and CXCR4 shows a 
downregulation of mRNA in the Deguelin group compared to the control, whereas anti-
inflammatory markers as IL-4 are upregulated. These findings were also seen in 
immunhistochemistry. Taken together this data support the assumption that an inhibition of 
HIF-1 leads to a positive effect on the graft due a lower inflammatory and also some anti-
inflammatory gene regulation.  
Interestingly, screening of histology slides of the Deguelin group shows many big macro-
phages, which cannot be found in this mass in the control. Nevertheless, a macrophage demo-
lition of the tissue is not observed. As PCR-data confirm a high upregulation of CD-163, a 
marker for anti-inflammatory macrophages, the addressed cells might be of an anti-
inflammatory M2-kind.
254
 This is also supported by the immunhistochemical staining that 
shows many of the CD-163 labeled macrophages in the Deguelin, but not the control group. 
Counting them displays a massive abundance in the Deguelin treated group, but none in the 
control. Fascinatingly, this findings do not match with an upregulation of IL-10 that is known 
to be often upregulated upon this anti-inflammatory processes,
73, 255
 whereas IL-4 is indeed 
upregulated. IL-4 has a two-sided role in transplantation processes – on the one hand it is 
known to play a role in anti-inflammatory immunemodulation
73
 and on the other hand it also 
modulates the Type 2 immune response in the process of chronic rejection
140
 which may lead 
to bronchiolitis obliterans. This fact is not uncommon, as the role of pro- and anti-
inflammatory interleukins can be different in several situations – depending on the fact, that 
higher IL-4 levels are correlated with anti-inflammatory macrophages of the M2-type let sug-
gest, that it has more the role as a factor of repair than destruction.
74, 75, 119
 
 
Despite this, we modified the method of lung transplantation we used. There are some points 
in the protocol of Zhai that showed difficulties in execution of the method. We have changed 
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the perfusion method over the Vena cava inferior to the directive perfusion over the heart 
(Figure 12) as this leads to less resistance of valves and directly flushes the heart-lung system 
by bypassing the body-circulation. Then, we have left a small part of the cuff tail because this 
guarantees a better manipulation of the cuff, without touching the cuff body that has to lie 
almost completely in the recipient’s vessel during transplantation (Figure 13 b). The last im-
portant change is the use of Prolene 6-0 threads for the ligation of the recipients structures 
instead of microaneurysm clamps (Figure 20). The most critical step is the unilateral damage 
by clamps in the small wound opening and the proximity of very vulnerable structures like the 
beating heart and the Nervus phrenicus. This brings the benefit of less danger of very big ob-
jects in the surgery field and faster removal of the threads which are just cut after all is fin-
ished.  
Via this modifications, we are able to decrease surgical irregularities that often end with the 
death of the recipient or suspension from the experiment.  
Our modified method shows increased survival over the observative time of 48 h. There is no 
change in the other death cause category, while the method by Zhai shows much higher mor-
tality due to surgical complications (Figure 23,Figure 24). 
The described technique of Zhai et al 
226
 shows some disadvantage especially for surgeons 
who are new in the field of microsurgery and not highly experienced in surgical techniques. 
Our two person surgery approach makes situations of loosing eye-contact to the microscopy 
field as for example for searching surgery tools or material, less necessary. Also the use of 
threads instead of clamps makes working in the small, always moving surgery field, much 
less complicated. The clamps present the risk of a big nonelastic body in direct contact to very 
sensible structures as the heart, the Nervus phrenicus or the structures of the vessels and the 
bronchus. During the surgery, three of these clamps would be necessary, while fixing and 
loosing the clamps is a skill of microsurgery most surgeons won’t be experienced with. Here, 
a high risk of generating damage by uncontrolled bouncing clamps is eliminated by our pro-
cedure.  
These changes lead to a much better outcome in animal survival. But not only the surgical 
complications, also the time saving is significant in the modified method. While the complete 
procedure of transplantation (time from the moment of end of cold ischemia until complete 
reperfusion) takes 23.36 ± 2.9 minutes according to the method of Zhai, only 11.82 ± 1.7 
minutes are needed now. This is of great interest, as the time of warm ischemia is a critical 
moment for damage to the graft and should be as short as possible. Compared to Zhais 
method, it is almost the same time span, but this might be due to the great knowledge in the 
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field of microsurgery and therefore the experienced skills of the surgeons as referring to their 
own information of their experience. This shows that at least, for surgeons who are new on 
the field of microsurgery, our modifications could be of interest to diminish failures that result 
from surgical complications. 
 
Table 21: Changes to Zhai’s technique compared to our method 
Zhai´s Method Modification Benefits 
Perfusion over the Vena cava 
inferior 
Perfusion over the 
right ventricle 
Bypass of the body circulation and 
direct perfusion of the heart-lung cir-
culation 
No cuff tail Short, but still re-
maining cuff tail 
Better control over the cuff body 
Using the same size of cuffs 
for all structures 
Using 17-G cuff for 
artery 
No piling up of blood in the lung by 
lower flow to the lung and faster flow 
away from it 
Using microaneurysm clips 
for ligation during surgery  
Using Prolene 6-0 
thread loops 
More space in the surgery field, time 
saving and less risk of damage 
 
Another interesting result is the anaesthesia of the surgical wound. The lung transplantation 
has special requirements on anaesthesia, due to the importance of good ventilation of the graft 
and therefore, a good breathing of the recipient. The use of strong analgesia, which is needed 
for a painful intervention as this, is necessary and usually requires the use of opioidanageltica, 
that are unfortunately known for their respiratory repressive effect. A willingly used anal-
getica is therefore buprenorphine, which has an acceptable effect endurance and shows no 
strong respiratory depression in most species – but it has a special effect on the rat, that makes 
its use not feasable. Different from the mouse, the rat shows a strong allophagic effect after 
buprenorphine injection
235
 which is so strong, that the animals almost kill themselves by eat-
ing every kind of bedding in their cage that can lead to rupture of the stomach. This effect is 
assumed to be a signal of a very acute nausea, which presents itself in this allophagia, com-
mon for most rodents.
235
 The alternative opioide piritramide makes the rats lethargic over a 
long time after anaesthesia and shows respiratory depression. To omit a presurgical injection 
of an opioide but to set a block of the local anesthesia ropivacain instead, results in a signifi-
cantly improved animal health score. The animals show almost no lethargic behaviour and 
therefore complete uninterrupted general condition and loading of the left side. Whereas the 
animals of the first, presurgical opioide treated group show clear signs of breathing problems, 
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probably due to the painful movement of the thorax, the animals with the local anesthesia 
block do not show such signs at all.  
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5 Conclusion and Outlook 
 
The model of orthotopic lung transplantation in the rat is a very effective way to investigate 
the diverse problems that occur during this process. It shows many advantages compared to 
other accepted models as for example the trachea graft, which has not the same validity for 
the fact, that the trachea is not part of the gas exchanging tissue. A difficulty is the surgery 
model itself as it needs a skilled surgeon with experience in microsurgery. Therefore, our 
changes to the old model may help to simplify this method and to make it more attractive 
even for more unexperienced surgeons on this field.  
We found that Deguelin is a potent drug to inhibit some deleterious effects responsible for 
early graft dysfunction. Furthermore, it has no acute toxic effects, neither on cell nor on the 
animals even after long time of intake. This leads to the conclusion, that the effects of this 
chemical compound could be interesting not only in cancer research but also in the very wide 
field of transplantation medicine.  
Futhermore, we found interesting effects on the immunomodulation via Deguelin treatment 
that could help preventing deleterious inflammation processes by activating the proinflamma-
tory macrophages. But is has still to be proven, if the long-time effects of this activation - es-
pecially under the influence of IL-4 –also leads to positive results in a long-term survival 
model.  
The role of the macrophages we found and their appearance in the lung is also an aspect that 
could be investigated further. To find out the source of the immigrated macrophages is of 
great pharmacological interest as their drug dependent recruitment may find application in a 
wide spectrum of inflammatory conditions. 
We also noticed a tendency for bleeding in the treated animals which might be due to the in-
fluence of HIF-1 on different factors like PAI-1 or other entities in the coagulation cascade.  
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6 Summary 
 
6.1 Summary 
Hypoxia is a dangerous condition for every organ and often cannot be completely avoided 
during surgical intervention. This is a result of ischemia which occurs when blood flow and, 
therefore, supply with the needed oxygen has to be interrupted for some time. During a trans-
plantation process, the ischemia is very severe as the organ has to completely removed from 
all supplying blood vessels and stored for hours in this case until the recipient is made ready. 
Due to this, ischemic damage and hypoxic condition is one of the important factors that influ-
ence the graft and can lead to primary graft dysfunction (PGD) which might end in the loss of 
function (bronchiolitis obliterans) or even the complete rejection of the organ. The loss of 
function is even more dramatic if the transplanted organ has to supply the complete organism 
with oxygen as the lung. Therefore, the reaction of a lung graft to the non-avoidable ischemic 
conditions and the role of hypoxia responding genes is crucial to refine the transplantation 
process. 
In this work we concentrate on the role of the hypoxia inducible factor 1 (HIF-1) and its gene 
product the vascular endothelial growth factor (VEGF) in the lung transplantation. It was al-
ready described earlier, that upregulation of VEGF showed a responsibility for the develop-
ment of edema in the lung and other pathological changes. Under this aspect an inhibition of 
HIF-1 as the main regulator of VEGF seems an interesting approach for the reduction of graft 
damage. Therefore the known rotenoid Deguelin, which was already described in its inhibito-
ry effects on HIF-1 concerning its vascular growth abilities in cancer research, was used. To 
investigate the effects under the most concrete clinical situation, our group established and 
refined an orthotope left lung lobe transplantation in the rat which was modified after an al-
ready known cuff-technique method of lung transplantation. This method bears the benefit 
that the lung is completely connected to all structures of the recipient and functions as a real 
lung lobe transplant over the observation time, different from other methods where only the 
contact to the foreign organism is guaranteed but not the ventilation or complete perfusion. 
Our modification on the microsurgial procedure in the rat bears furthermore some advantages 
especially for scientists that are new on the field of microsurgery. We could demonstrate that 
these modifications bear fewer risks of complications and, thus, fewer cases of early terminat-
ed animals during the experiment. Also the needed time for the transplantation process, which 
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is essential to keep warm ischemia as short as possible was equal compared to the other meth-
od. The pain management we used in our method avoided a presurgical injection of an opioid 
which always made a respiratory depression that was dangerous for the recovery during the 
first hours after transplantation. We could demonstrate that our intercostals block with a local 
anesthetic resulted in much better animal health compared to a classical presurgical opioid-
injection.  
Concerning the effects of Deguelin, we could show that Deguelin significantly inhibited HIF-
1 reporter genes as VEGF, Carbonic anhydrase IX (CAIX), lysyl oxidase (LOX), 
Angiopoietin related protein 4 (ANGPTL4), Egl nine homolog 3 (EGLN3) and 
Adrenomedullin (ADM) in a concentration dependent manner in vitro. It also suppressed 
mRNA levels of VEGF, chemokine receptor type 4 (CXCR4) and intercellular adhesion mol-
ecule 1 (ICAM-1) in the ischemic lung. Furthermore, the VEGF modulated reperfusion edema 
was significantly less pronounced in lungs and a much higher survival rate was observed for 
Deguelin treated animals. In addition, under Deguelin treatment, proinflammatory proteins 
such as ICAM-1 and CXCR4 were down-regulated and anti-inflammatory monocytes (CD 
163, CD 68) were recruited to the transplanted organ. 
These findings were underlined by the significant higher survival rate of Deguelin treated 
animals compared to the untreated ones. This let us suggest that HIF-1 inhibition can improve 
the condition of the lung graft. 
6.2 Zusammenfassung 
Für alle Organe ist Hypoxie ein gefährlicher Zustand, der sich allerdings gerade während chi-
rurgischen Eingriffen oft nicht vermeiden lässt. Die bei Eingriffen oft durch Unterbrechung 
der Blutversorgung auftretende Ischämie führt durch den versiegenden Zustrom von frischem, 
sauerstoffreichem Blut zur Hypoxie. Besonders Transplantate sind aufgrund der Entfernung 
aus dem Spender und der oft längeren Lagerung bis zur Vorbereitung des Spenders, von einer 
extremen Ischämie betroffen. Diese unvermeidliche Ischämie ist auch oft der Grund für die 
Schäden durch Hypoxie und Ischämie die sich bei der Reperfusion des Organs im Spender 
präsentieren. Diese Ischämie- und Reperfusionsschäden führen häufig zu Folgeschäden wie 
der Primären Transplantat Dysfunktion (Primary Graft Dysfunction PGD) die einen Funkti-
onsverlust zur Folge hat ( z.B. die Bronchiolitis obliterans in der Lunge) und auch im kom-
pletten Transplantatverlust gipfeln kann. Dieser Funktionsverlust ist besonders dramatisch 
wenn das transplantierte Organ eine Versorgerfunktion für den gesamten Organismus innehat, 
wie es bei der Lunge der Fall ist. Daher ist die genaue Reaktion des Transplantats auf die 
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nicht zu vermeidende Ischämie und die Rolle der auf Hypoxie reagierenden Gene von beson-
derem Interesse um Folgeschäden zu vermindern und den Transplantationsprozess stetig zu 
verbessern.  
Diese Arbeit beschäftigt sich daher mit der Rolle des Hypoxia Inducible Faktors-1 (HIF-1) 
und seines Genprodukts, dem Vascular Endothelial Growth Factor (VEGF) in der Lungen-
transplantation. Es wurde bereits beschrieben dass die Raufregulation von VEGF mit der 
Ödembildung und anderen pathologischen Veränderungen in der Lunge zusammenhängt. Un-
ter Anbetracht dieser Tatsache scheint eine Inhibition von HIF-1 als Hauptregulator von 
VEGF ein interessanter Ansatz bei der Verminderung von Transplantatschäden in der Lunge 
zu sein. Als Inhibitor wurde ein bereits in der Krebsforschung als HIF-1 Inhibitor 
beschriebendes Rotenoid namens Deguelin verwendet, das in den Studien vor allem eine Ge-
fäßwachstum hemmende Wirkung in Bezug auf HIF-1 zeigte.  
Um die Auswirkung einer Hemmung unter möglichst kliniknahen Bedingungen zu untersu-
chen wurde von unserer Arbeitsgruppe ein Transplantationsmodell an der Ratte etabliert und 
modifiziert, bei dem der linke Lungenflügel orthotop transplantiert wurde. Dieses Modell hat 
den Vorteil einer sehr realen Transplantationsbeobachtungen, bei der das Transplantat kom-
plett an den Kreislauf des Empfängers angeschlossen und somit funktionstüchtig ist, anders 
als bei vielen anderen Modellen, bei denen nur sehr geringer Kontakt zum Empfänger besteht 
und oft keine Ventilation  und komplette Perfusion der transplantierten Lunge gegeben ist. 
Die Transplantationsmethode wurde nach einer früher beschriebenen Cuff-Methode modifi-
ziert, um einige auftretende Komplikationen zu verbessern.  Die Veränderungen zeigten eine 
deutliche Verbesserung in Bezug auf chirurgische Komplikationen und somit weniger Tiere, 
die aufgrund dieser vom Versuch ausgeschlossen werden mussten. Die dafür benötigte Zeit 
für die Transplantation, die aufgrund der eintretenden warmen Ischämie, entscheidend ist, 
unterschied sich nicht von der Methode die unserer zugrunde lag. Die Schmerztherapie die 
wir verwendeten vermied eine präoperative Opioidinjektion um die darauf folgende Atemde-
pression zu vermeiden die besonders in den ersten Stunden nach Transplantation gefährlich 
war. Wir konnten zeigen das ein Interkostaler Nervenblick mit einem Lokalanästhetikum zu 
einer Verbesserung des Animal-Health Scores führte verglichen mit einer präoperativen 
Opoidinjektion.  
Bezüglich der Effekte von Deguelin auf die untersuchten Tiere konnten wir zeigen, das eine 
in vitro Deguelingabe zu einer signifikanten konzentrationsabhängigen Inhibition von HIF-1 
Reportergenen wie VEGF, Carboanhydrase IX (CAIX), Lysyloxidase (LOX), Angiopoietin 
related protein 4 (ANGPTL4), Egl nine homolog 3 (EGLN3) und Adrenomedullin (ADM) 
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führt. Außerdem konnten wir eine mit der Deguelingabe zusammenhängende 
Runterregulation von mRNA von VEGF, Chemokine Receptor Type 4 (CXCR4) und 
Intercellular Adhesion Molecule 1 (ICAM-1) in der ischämischen Lunge feststellen. Deswei-
teren zeigte sich eine deutliche Verminderung des VEGF modulierten Reperfusionsödems bei 
den mit Deguelin behandelten Tieren. Unter Deguelingabe zeigte sich auch eine 
Runterregulation von proinflammatorischen Proteinen wie ICAM-1 und CXCR4 feststellen, 
während antiinflammatorische Monozyten (CD 163, CD 68) scheinbar unter Deguelingabe in 
das transplantierte Organ rekrutiert wurden.  
Diese Erkenntnisse in Verbindung mit der deutliche besseren Überlebensrate der mit 
Deguelin behandelten Tiere, lassen den Schluss zu, das eine Inhibition von HIF-1 eine Ver-
besserung für das Lungentransplantat darstellt und Schäden vermindern kann.  
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8 Addendum 
8.1 Materials 
 
Name Manufacturer Location 
LTX 
Adrenalin 1:100 Pharmacy of the JWG-
University 
Frankfurt am Main 
Alm rectractor 5.5 mm FST Heidelberg, Germany 
Animal clipper (Aesculap Action Ex-
acta) 
Aesculap Tuttlingen, Germany 
Atropin Braun Melsungen Melsungen, Germany 
Buprenorphine Reckitt Benckiser Mannheim, Germany 
Cold light source CL-200 Schott AG Mainz, Germany 
Corn oil (Mazola) Unilever Hamburg, Germany 
Crile-Wood Needleholder 13mm; 1.5 
mm 
FST Heidelberg, Germany 
Deguelin Sigma GmbH/Enzo Life 
Science 
Steinheim/Lörrach, 
Germany 
Enrofloxacin (Baytril) Bayer Leverkusen, Germany 
Extra fine Graefe Forceps 0.5 mm FST Heidelberg, Germany 
Halsted Mosquito Forceps Eickemeyer Tuttlingen, Germany 
Heparine 25.000 I.U. Ratiopharm GmbH Ulm, Germany 
Isoflurane evaporator ‘ Vapor 19.3’ Dräger Lübeck, Germany 
Ketamin Pfizer Berlin, Germany 
Mayo Scissor  FST Heidelberg, Germany 
Metzenbaum Baby Scissor FST Heidelberg, Germany 
Metzenbaum Scissor FST Heidelberg, Germany  
Moria Iris Forceps 0.5 mm FST Heidelberg, Germany 
Moria Iris Scissor FST Heidelberg, Germany 
Narrow pattern forceps 14.5 cm FST Heidelberg, Germany 
Perfadex (R) vitrolife Göteborg, Sweden  
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Piritramid ( Dipidolor) Jannsen Pewaukee, USA 
Polidon-Jod (Braunol) Braun Melsungen Melsungen, Germany 
Ringer-Infusion Solution Braun-Melsungen Melsungen, Germany 
Ropivacain (Naropin) Astra Zeneca Wedel, Germany 
Small animal ventilator RUS-13  Föhr Medical Instru-
ments  
Pohlheim, Germany  
Spencer  ligature Scissor FST Heidelberg, Germany 
Standard Scissor blunt FST Heidelberg, Germany 
Sterile gauze compresse Beesana Barsbüttel, Germany 
Strong forceps 1x2 teeth, curved 14 
cm 
FST Heidelberg, Germany 
Tissue Forceps 1x2 Teeth 14.5 cm FST Heidelberg, Germany 
Vannas Spring Scissor 2mm cutting 
edge 
FST Heidelberg, Germany 
Xylazin Bayer Healthcare Leverkusen, Germany 
 
Histology 
Acetic acid concentrated J.T. Baker Griesheim, Germany 
Avidin-Biotin-Blocking Kit Vector labs Burlingame, USA 
Cover glass  Menzel GmbH Braunschweig, Ger-
many 
DAB-Substrate Kit for Peroxidase  Vector labs Burlingame, USA 
DPX (R) Merck Darmstadt, Germany 
Embedding cassettes  Sanowa Leimen, Germany 
Embedding machine Medax Salt Lake City, USA 
Eosin –Y Carl Roth Karlsruhe, Germany 
Ethanol absolute Sigma-Aldrich  Seelze, Germany 
Formaldehyde 36.5 %  Carl Roth Karlsruhe, Germany 
Goat Serum Vector labs Burlingame, USA 
Goat anti mouse secondary antibody 
HRP-labeled (PO447) 
Dako(biozol diagnostica) Eching, Germany 
Heating Plate Medax Salt Lake City, USA 
Histology mold Medite online Burgdorf, Germany 
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Hydrochloric acid AppliChem Darmstadt, Germany 
Hydrogen peroxide 30% AppliChem Darmstadt, Germany 
Imm Edge Hydrophobic Barrier Pen Vector labs Burlingame, USA 
Macrophage/Dendritic cells Antigen 
ABIN 289947 
Antibodies – online 
GmbH 
Aachen, Germany 
Mayers hematoxylin AppliChem Darmstadt, Deutsch-
land 
Methylbenzoat  Carl Roth Karlsruhe, Germany 
Microtome (Leica RM 2125RT) Leica  Nussloch, Deutschland 
Microtome Blades R 35 FEATHER Osaka, Japan 
Mouse anti rat CD163 monoclonal  
(MCA342R) primary antibody 
AbD Serotec Düsseldorf, Germany 
Mouse anti rat CD 68 monoclonal 
(MAB1435) primary antibody 
Chemicon International  
(Millipore) 
Schwalbach, Germany 
Mouse anti rat ICAM-1 monoclonal 
(LS-C45355) primary antibody 
LSBioscience Seattle, USA 
Rabbit anti rat CXCR4 polyclonal 
(ab2074) primary antibody  
abcam Cambridge, UK 
Rabbit Serum Vector labs Burlingame, USA 
RotiClear ® Roth Karlsruhe, Deutsch-
land 
Roti-Mount Aqua Roth Karlsruhe, Deutsch-
land 
Slides Super Frost Plus ® Menzel GmbH Braunschweig, 
Deutschland 
Slides Süsse Frost ® Süsse Gudenberg, Deutsch-
land 
Unmasking Solution Vector labs Burlingame, USA 
Vectastain ABC-Peroxidase Kit Vector labs Burlingame, USA 
Vectastain Elite ABC Kit Rabbit IgG 
(Pk-6102) 
Vector labs  Burlingame, USA 
Waterbath Daeglef Patz KG Wankendorf, Germany 
Xylol  Carl Roth Karlsruhe, Germany 
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Western Blot 
Acrylamide 30% Applichem Darmstadt, Germany 
Ammoniumpersulfate for 
electrophoresis (APS) 
Sigma-Aldrich Seelze, Germany 
ß-Actin antibody N21 rabbit poly-
clonal  
Santa Cruz  Heidelberg, Germany 
BCA-Kit Pierce/Thermo-Fischer 
Scientific 
Bonn, Germany 
BSA Carl Roth Karlsruhe, Germany 
Bradford Solution (RotiQuant) Carl Roth Karlsruhe, Germany 
ß-Mercaptoethanol Carl Roth Karlsruhe, Germany 
Bromophenolblue Sigma-Aldrich Seelze, Germany 
Dithiothreitol (DTT) Applichem Darmstadt, Germany 
GAPDH FL 335 antibody rabbit 
polyclonal  
Santa Cruz  Heidelberg, Germany 
Glycerol Carl Roth  Karlsruhe, Germany 
HIF-1 alpha 67 antibody 
abcam 
Cambridge, UK 
HIF-1 alpha clone 54 antibody 
BD bioscience 
Heidelberg, Germany 
IgG-HRP Sc2005 anti mouse 
Santa Cruz 
Heidelberg, Germany 
IgG-HRP Sc 2004 goat anti rabbit  
Santa Cruz  
Heidelberg, Germany 
Implen NanoPhotometer Implen  München, Germany  
Kaliumchloride Carl Roth Karlsruhe, Germany 
Kaliumhydrogenphosphate Carl Roth Karlsruhe, Germany 
Westernblot Luminol Reagent Santa Cruz Heidelberg, Germany 
mAbcam 68334 VEGF antibody 
abcam 
Cambridge, UK 
Magic Mark XP WB standard  Invitrogen Darmstadt, Germany 
Methanol Carl Roth Karlsruhe, Germany 
MINI PROTEAN CELL 3 Biorad München, Germany 
Natriumchloride Carl Roth Karlsruhe, Germany 
Natrumdihydrogenphosphate Carl Roth Karlsruhe, Germany 
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Natriumpyrophosphate   Carl Roth Karlsruhe, Germany 
Natriumvanadate  Carl Roth Karlsruhe, Germany 
Nitrocellulosemembrane Hypond C 
Extra 
Amersham Freiburg, Germany  
PBS-tablets  Sigma-Aldrich Seelze, Germany 
Phenylmethylsulfonylfluoride 
(PMSF) 
Sigma-Aldrich Seelze, Germany 
Ponceau-Red Sigma-Aldrich Seelze, Germany 
Protease Inhibitor Cocktail Tablets Roche Mannheim, Germany 
Restore Westernblot Stripping 
Buffer 
Pierce/Thermo-Fischer 
Scientific 
Bonn, Germany 
Sodiumdodecylsulfate  (SDS 20%) Sigma-Aldrich Seelze, Germany 
Sigma 7-9 Sigma-Aldrich Seelze, Germany 
Spectra Brood Range Marker Fermentas  St. Leon-Rot, Germa-
ny 
Spectrophotometer µQuant Biotech Germany Bad Friedrichshall, 
Germany 
TEMED Carl Roth Karlsruhe, Germany 
TWEEN-20 Sigma Aldrich Seelze, Germany 
Tris Carl Roth Karlsruhe, Germany 
Triton X-100 Applichem Darmstadt, Germany 
Urea  Sigma Aldrich Seelze, Germany 
   
Cell culture 
Cell flask 175 cm² Greiner Bio One  Frickenhausen, Ger-
many 
Disposable cell scraper Greiner Bio One  Frickenhausen, Ger-
many 
DMSO for cell culture Sigma-Aldrich  Seelze, Germany 
Epidermal Growth Factor (EGF) BD bioscience Heidelberg, Germany 
Fetal bovine calve serum gold PAA Pasching, Austria 
HERA bench Thermo Scientific   
HMEC  ATCC Manassas, USA 
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HTB-177  human lung epithelial cells  ATCC Manassas, USA 
Hydrocortison   
Hypoxia chamber INVIVO2 400 Hy-
poxia Workstation 
Ruskinn Technology 
LTD  
Pencoed, UK  
MCDB 131 without L-Glutamin Gibco Darmstadt, Germany 
Penicillin/Streptavidin solution Sigma Aldrich Seelze, Germany 
Petri dish (6 cm) Greiner Bio One  Frickenhausen, Ger-
many 
RPMI 1640 Medium PAA Laboratories  Pasching, Austria 
PBS PAA Laboratories Pasching, Austria 
Trypsin-EDTA Lonza  Basel, Switzerland 
 
PCR 
Chloroform Sigma-Aldrich 
Biochemistry 
Hamburg, Deutschland 
DEPC-treated water Fermentas St. Leon-Rot, Germa-
ny 
Isopropyl alcohol Carl Roth Karlsruhe, Germany 
i-Script cDNA synthesis kit Biorad München, Germany 
Oligonucleotide primers Sigma Aldrich Hamburg, Deutschland 
PCR-water Eppendorf  Wesseling-Berzdorf, 
Germany 
PowerSYBR Green PCR Master Mix Applied Biosystems Carlsbad, California, 
USA 
PCR-Realttime Step-One Plus  Applied Biosystems  Carlsbad, California, 
USA 
Thermocylcer Veriti  96 well fast  Applied Biosystems  Carlsbad, California, 
USA 
TriReagent Sigma-Aldrich 
Biochemistry 
 
Hamburg, Deutschland 
Consumable supplies 
Eppendorf tubes  Sarstedt Nümbrecht, Germany 
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Falcon tubes 15/50 ml Greiner Bio-one Frickenhausen, Ger-
many 
Gloves non sterile nitrile/latex Ansell Brüssel, Belgium 
Parafilm ‘M’  Pechiney plastic bagga-
ging  
Chicago, USA  
Pipette tips  Starlab Ahrensburg, Germany 
Stripette Sigma-Aldrich Steinheim, Germany 
 
Statistical analysis 
Graph Pad Prism (R) 5.02 software Graph Pad Software Inc. La Jolla, USA 
 
Computer software 
Adobe Photoshop CS5.1 Adobe  München, Germany 
Endnote Adept Science Frankfurt, Germany 
Graph Pad Prism (R) 5.02  Graph Pad Software Inc.  La Jolla, USA 
Image J Software (Freeware)   
Leica Application Software V 3.8 Leica Wetzlar, Germany 
Matlab  The Mathworks Nattick, USA 
Step One Software v.2.1. Applied Biosystems  Carlsbad, California, 
USA 
Windows Excel Microsoft München, Germany 
Windows Paint Microsoft München, Germany 
Windows Word Microsoft München, Germany 
 
Equipment 
Centrifuge 5702 Eppendorf  Wesseling-Berzdorf, 
Germany 
Centrifuge  5417R Eppendorf Wesseling-Berzdorf, 
Germany 
Centrifuge Multifuge 1S-R  Thermo-Scientific  Bonn, Germany 
Centrifuge ‘The butterfly rotor’ Carl Roth  Karlsruhe, Germany 
Fine scale Sartorius  Goettingen, Germany 
Heating Thermomixer  MHR 23  HLC (DITABIS AG)  Pforzheim, Germany  
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HERA cell 15 0i CO2 incubator  Thermo Scientific  Bonn, Germany 
HERA bench Thermo-Scientific  Bonn, Germany 
Kodak Image Station 4000 MM Pro Carestream  New York, USA  
Incubator B15  Thermo Scientific  Bonn, Germany 
Isoflurane Vaporator Drägerwerk  Lübeck, Germany  
PCR-Realttime Step-One Plus  Applied Biosystems  Carlsbad, California, 
USA 
Photometer   
Pipette 1000/200/100/10 µl  Eppendorf  Wesseling-Berzdorf, 
Germany 
Pipetus – akku  Hirschmann Laborgeräte Eberstadt, Germany  
Microscope Module CTR 5000 Leica  Wetzlar, Germany  
Microscope DM 5000 B Leica  Wetzlar, Germany  
Microscope surgery Zeiss München, Germany 
MINI Protean cell for Westernblot BioRad München, Germany 
Roller mixer SRT9D Stuart  Dublin, Ireland  
Shaking platform ST5  CAT  Staufen, Germany  
Small animal ventilator Drägerwerk  Lübeck, Germany 
SonoPlus Sonificator Bandelin  Berlin, Germany 
Spectrophotometer µQuant 
Microplate 
Bio-Tek Instruments Inc.  Bad Friedrichshall, 
Germany 
Tank transfer system for blotting BioRad München, Germany 
Thermocylcer Veriti  96 well fast  Applied Biosystems  Carlsbad, California, 
USA 
Vacuum safety pump system AA 02  HLC (DITABIS AG)  Pforzheim, Germany 
Vortexer  VWR International  Darmstadt, Germany 
Ultraturrax T10 Basic IKA Laboratory Equip-
ment 
Staufen, Germany  
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8.2 Abbreviations 
 
Abbreviation Name 
AAMR Acute antibody mediated rejection 
ACTB Gene name of ß-Actin 
ADM Adrenomedullin 
ANGPTL4 Angiopoietin-related protein 4 
APS Ammoniumpersulate 
APC Antigen presenting cells 
ARNT Aryl hydrocarbon receptor nuclear 
translocator 
ATP Adenosinetriphosphate 
BCA Bicinchoninic acid protein assay 
BOS Bronchiolitis obliterans syndrome 
bHLH Basic HELIX-LOOP-HELIX 
BSA Bovine serum albumine 
BW Bodyweight 
°C Degree in celsius 
CAIX Carboanhydrase 9 
CD Cluster of differentiation 
cDNA Complementary DNA 
CO2 Carbondioxide 
CXCR-4 Chemokin receptor type 4 
d Days 
DAB 3,3’-diaminobenzidin 
DEC Deleted in colorectal cancer gene 
DEPC Diethylpyrocarbonat 
DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGLN3 Egl nine homolog 3 gene 
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EIP Etoposide induced protein 
EPO Erythropoietin 
ET1 Endothelin-1 
FCS Fetal calve serum 
G Gauge 
g Gram 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GLUT1 Glucose transporter 1 
h Hours 
HCL Hydrochloric acid 
HIF-1 Hypoxia inducible factor 1  
H&E Hematoxlyin&Eosin  
HLA Human leukocyte antigen 
HMEC Human microvascular endothelial cells 
HRE Hypoxia responsible element 
HRP Horseradish peroxidase 
ICAM -1 Intercellular adhesion molecule-1 
ICU Intensive care unit 
IFN Interferon 
IGF Insuline growth factor 
Ig Immuneglobuline 
i.g. Intragastrical 
IL Interleukin 
IRI Ischemia and reperfusion injury 
I/R Ischemia/reperfusion 
IU International units 
K
+ Kalium ionised 
KCL Kaliumchloride 
kDa KiloDalton 
kg Kilogram 
KH2PO4 Kaliumhydrogenphosphate 
KRT keratin 
i.v. intravenous 
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LD50 Lethal dose 50 
LEP Leptin 
LOX Lysyl oxidase 
LRP1 LDL-receptor related protein  
LTX Lung transplantation 
M. Musculus 
M Molar 
Mm. Musculi 
mm Millimeter 
MAPK P38 mitogen activated kinase 
MDR1 Multidrug resistance receptor 1  
MHC Major histocompatibility complex 
min Minutes 
MCP-1 Monocyte chemotactic protein-1 
ml Milliliter 
mRNA Messenger RNA 
n Number 
N. Nervus 
Na
+ Natrium ionised 
Na2PO4 Natriumdiphosphate 
NaCl Natriumchloride 
NADPH Nicotinamidadenindinukleotidphosphat 
NF-КB Nuclear factor ‘kappa-light-chain-enhancer’ 
nM nanomolar 
NOS Nitrogen monoxide synthase 
O2 Oxygen 
OB Obliterative bronchiolitis 
ODD Oxygen dependent degradation domain 
ODC 12-O-tetradecarnoylphorbol-13-acetat in-
duced ornithine decarboxylase 
OPTN Organ procurement and transplantation net-
work 
PAI-1 Plasminogen activator inhibitor -1 
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PCR Polymerase chain reaction 
PBS Phosphate buffered saline 
PEEP Positive end expiratory pressure 
PER Periodic circadian protein 
PGD Primary graft dysfunction 
PI3K Phosphositide-3-Kinase 
PMSF Phenylmethylsulfonylfluoride 
ppm Parts per million 
RANTES Regulated upon Activation, Normal T-Cell 
Expressed and Secreted 
RNA Ribonucleidacid 
ROS Reactive oxygen species  
rpm Rounds per minute 
s.c. Subcutaneous 
SDS Sodiumdodecylsulfate 
PAGE Polyacrylamide gel electrophoresis 
SHAM Control group 
SIM Single-minded protein 
TBS Tris-buffered saline  
TBS-T Tris-buffered saline with TWEEN 
TGF Transforming growth factor 
TLR Toll-like receptor 
TPI Triosephosphate isomerase 
TNF-α Tumor necrosis factor α 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF Vascular endothelial growth factor 
VHL Von Hippel-Lindau tumor suppressor gene 
pVHL Product of VHL  
VIM Vimentin 
μ Micro 
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